Week 1 · Module 1
Field medical diagnostic
Twenty-four questions on the boundary, the materials, the review process and the intelligence the function produces
Your scenario
A field medical colleague shows a slide summarising a Phase II study of an unapproved indication. The clinician asked about it, the data are published, and the slide is accurate. The slide was still not approved for proactive use — and a field deck is proactive material by definition, whatever prompted its display.
What this course covers
Field medical teams — medical science liaisons and their equivalents — sit closer to the promotion boundary than any other scientific role, and their materials carry the sharpest constraints in the industry. A slide that would be unremarkable in a manuscript can be non-compliant in a field deck.
This course covers the boundary itself, the material types, surviving medical–legal–regulatory review, and the insight reporting that is the function's most under-taught output.
Take the diagnostic honestly
Do not look anything up. A wrong answer is worth more than a right one, because it is the only way to find the gap.
—
—
Your ten areas — study the red ones first
Before you move on
Write down your three weakest areas.
Next module
1.2 — Scientific exchange and its boundary
Week 1 · Module 2
Scientific exchange and its boundary
The line is not drawn by job title, setting or sincerity. It is drawn by purpose and content
Your scenario
A field medical professional says: “The tolerability profile has been really good in practice — most of my clinicians are very happy with it.” Every word is sincerely meant. It is an unreferenced favourable characterisation, delivered proactively, and it is promotion — spoken by someone whose entire role depends on not doing that.
Where the line sits
Figure 1.2 — The boundary. Both columns are legitimate activities; they are simply different functions with different rules and different approval routes. The failure mode is not a field medical professional doing promotion deliberately — it is one adding a favourable adjective to an accurate statement.
What converts exchange into promotion
Promotion
Exchange
The tolerability profile has been really goodunreferenced judgement
Grade ≥3 events occurred in 147/389 patients (37.8%) versus 121/388 (31.2%) [reference]
Most clinicians are very happy with itanecdote as evidence
— delete; there is no data behind it
It performs better than the alternativescomparative, no head-to-head
No head-to-head comparative data are available
You should consider it for these patientsa recommendation
The approved indication covers this population [label reference]
The subgroup data are really compelling
The interaction was significant (p=0.03) but was one of six prespecified analyses in a trial not powered for it
Independence is structural, not personal
Field medical must sit outside the commercial reporting line and outside commercial incentives. That means no sales targets, no prescribing-volume metrics, no involvement in pricing or formulary negotiation, and no compensation tied to product uptake.
This is not a statement about anyone's integrity. It is the structural condition that makes the function's independence credible to a regulator — and it is one of the first things an inspection examines.
This is not a statement about anyone's integrity. It is the structural condition that makes the function's independence credible to a regulator — and it is one of the first things an inspection examines.
Drills
Drill 1 of 3
Which statement stays within scientific exchange?
A“Grade ≥3 events occurred in 37.8% versus 31.2% in the pivotal trial [reference].”
B“In my experience it’s very well tolerated.”
C“You should think about it for your frailer patients.”
D“It compares favourably with what you’re using now.”
Drill 2 of 3
A commercial colleague asks the field medical team to visit a high-prescribing clinician who is "wavering". What is the issue?
ANone — the visit is scientific
BThe visit would be directed by a commercial objective, compromising independence
COnly a problem if it happens near a tender
DOnly a problem if it is not documented
Drill 3 of 3
A clinician asks, unprompted, about an unapproved use. What is the correct handling?
AShow the relevant slide from the field deck
BSay you cannot discuss it and change the subject
CRoute it through the medical information process
DPass it to the sales representative
Compliance Governance The Regulatory Boundary: Proactive vs. Reactive Scientific Exchange
Field medical writers must navigate the strict legal line between commercial promotion and non-promotional scientific exchange (governed by FDA 21 CFR 312/314, OIG Compliance Guidance, and EFPIA/ABPI Codes):
| Domain Parameter | Proactive Interaction (Commercial / Field Reps) | Reactive Scientific Exchange (MSLs / Medical Affairs) |
|---|---|---|
| Initiation Mechanism | Company-initiated outreach to Healthcare Providers (HCPs) or formulary decision-makers. | Strictly HCP-initiated, unsolicited request for off-label or pipeline information. |
| Permitted Content Scope | Strictly limited to approved label indications, approved dosages, and on-label safety profiles. | Unapproved indications, off-label dosing, pipeline phase II/III data, mechanistic scientific discussions. |
| Material Tone & Format | Persuasive, promotional, branded layout, fair balance warnings clearly juxtaposed. | Scientific, balanced, non-promotional, peer-reviewed reprints, standard response letters (SRLs). |
| MLR / PRC Review Code | Review for promotional substantiation, FDA OPDP submission (Form FDA 2253). | Review for scientific rigor, balance, objective presentation, absence of commercial call-to-action. |
Production drill
Rewrite each spoken line so it stays within scientific exchange, or say it should not be said at all.
1. "The efficacy data are really impressive — a 34% risk reduction."
2. "Most of the specialists I speak to have switched."
3. "It's much better tolerated than the older agents."
4. "The subgroup data suggest you should be testing everyone before treatment."
5. "We're expecting approval in the second-line setting next year."
6. "Honestly, I'd use it for this patient."
2. "Most of the specialists I speak to have switched."
3. "It's much better tolerated than the older agents."
4. "The subgroup data suggest you should be testing everyone before treatment."
5. "We're expecting approval in the second-line setting next year."
6. "Honestly, I'd use it for this patient."
1. Rewrite: “The hazard ratio for progression-free survival was 0.66, with a 95% confidence interval of 0.53 to 0.82 [reference].” — “Really impressive” is a judgement. Also, a hazard ratio of 0.66 is not straightforwardly a 34% risk reduction; give the estimate and let the clinician interpret it.
2. Do not say it. Anecdote about other clinicians' behaviour, presented as evidence, with a clear promotional purpose. There is no rewrite that saves it.
3. Rewrite: “No head-to-head comparative data are available. In the pivotal trial, grade ≥3 events occurred in 37.8% versus 31.2% with placebo [reference].” — The original is a comparative claim with no head-to-head basis.
4. Rewrite: “A significant interaction by biomarker status was observed, but it was one of six prespecified subgroup analyses in a trial not powered for interaction, so it is hypothesis-generating [reference].” — The original recommends a practice change from a subgroup.
5. Do not say it. Pre-approval communication about an unapproved indication, including expected timing. Nothing rescues this one.
6. Do not say it. Individual treatment advice, and a personal endorsement. If asked directly, the answer is that treatment decisions are theirs and you can provide the data that inform them.
Three of six cannot be rewritten. That is the honest proportion: some things are not a wording problem. Recognising which is which is the skill this module is teaching — and lines 2 and 6 are the ones people say without noticing, because they sound like ordinary professional conversation.
2. Do not say it. Anecdote about other clinicians' behaviour, presented as evidence, with a clear promotional purpose. There is no rewrite that saves it.
3. Rewrite: “No head-to-head comparative data are available. In the pivotal trial, grade ≥3 events occurred in 37.8% versus 31.2% with placebo [reference].” — The original is a comparative claim with no head-to-head basis.
4. Rewrite: “A significant interaction by biomarker status was observed, but it was one of six prespecified subgroup analyses in a trial not powered for interaction, so it is hypothesis-generating [reference].” — The original recommends a practice change from a subgroup.
5. Do not say it. Pre-approval communication about an unapproved indication, including expected timing. Nothing rescues this one.
6. Do not say it. Individual treatment advice, and a personal endorsement. If asked directly, the answer is that treatment decisions are theirs and you can provide the data that inform them.
Three of six cannot be rewritten. That is the honest proportion: some things are not a wording problem. Recognising which is which is the skill this module is teaching — and lines 2 and 6 are the ones people say without noticing, because they sound like ordinary professional conversation.
Reflection
Think of a scientific conversation you have had about a product. Did any adjective creep in that would not survive this test?
Next module
1.3 — The field medical toolkit
Week 1 · Module 3
The field medical toolkit
What materials the function uses, who owns each one, and which ones must never cross the boundary in either direction
Your scenario
A field medical professional uses a promotional detail aid because it presents the efficacy data more clearly than the scientific deck. The content is accurate and approved — approved as promotional material, through the commercial route, for use by the commercial team. Using it blurs the exact boundary the function exists to hold.
The toolkit
| Material | Purpose | Notes |
|---|---|---|
| Scientific slide deck | Balanced dialogue on approved uses | The core asset. Every claim referenced; front matter states intended use. |
| FAQ document | Consistent answers to anticipated questions | Reactive content may be included but must be marked reactive-only |
| Congress summary | Reporting new data from a meeting | Requires its own review; public presentation does not exempt it |
| Publication reprints | Sharing peer-reviewed evidence | Licence required; off-label reprints restricted and market-dependent |
| Scientific engagement guide | Structuring dialogue on approved topics | Not a script and not objection handling |
| Advisory board materials | Framing a genuine advisory question | Must seek advice, not deliver messages |
| Insight capture template | Recording actionable observations | Structured, aggregated, reported to medical strategy |
Two materials that must not cross
Promotional detail aids do not come into field medical use. They were approved as promotional material, through a different route, for a different function. Using one collapses the distinction that justifies the field medical role existing separately.
Field scientific decks do not go to the commercial team. They contain balance, limitations and sometimes reactive content that promotional use rules do not permit. In practice this is the direction that leaks more often.
Field scientific decks do not go to the commercial team. They contain balance, limitations and sometimes reactive content that promotional use rules do not permit. In practice this is the direction that leaks more often.
Drills
Drill 1 of 3
A field medical professional wants to use a promotional detail aid because its efficacy figure is clearer. What is the problem?
ANone — the content is approved
BOnly a problem if the detail aid is out of date
COnly a problem if the clinician is a prescriber
DIt was approved for a different function through a different route
Drill 2 of 3
A congress summary deck is prepared from data presented publicly last week. What review does it need?
AFull MLR review, with off-label content excluded
BNone — the data are public
CA quick check by one medical reviewer
DApproval from the congress organisers
Drill 3 of 3
May a field FAQ document contain answers to off-label questions?
AYes, and they may be used like any other content
BYes, if clearly designated reactive-only and never volunteered
CNever, in any form
DYes, if the clinician is a specialist
Production drill
For each request, name the correct material and say what must not be used.
1. A clinician wants to discuss the pivotal trial's safety profile.
2. A clinician asks for a copy of the primary publication.
3. A clinician asks about a use outside the label.
4. The team wants expert input on how to design a real-world study.
5. A clinician mentions that sequencing after second-line failure is unclear in their centre.
6. A commercial colleague asks for the field scientific deck to use on calls.
2. A clinician asks for a copy of the primary publication.
3. A clinician asks about a use outside the label.
4. The team wants expert input on how to design a real-world study.
5. A clinician mentions that sequencing after second-line failure is unclear in their centre.
6. A commercial colleague asks for the field scientific deck to use on calls.
1. Scientific slide deck, safety section, every figure referenced. Not the promotional detail aid, however much clearer its chart.
2. A licensed reprint of the publication. Check the licence covers this use and this market. Not a PDF downloaded and forwarded without a licence — that is a copyright issue on top of everything else.
3. The medical information process. Not the field deck, and not the FAQ document unless it contains designated reactive-only content and the question was genuinely unsolicited.
4. Advisory board materials, with a defined advisory question and documented expertise-based selection. Not a meeting convened to present data to influential clinicians — that is a promotional activity wearing an advisory board's clothes.
5. Insight capture. This is a genuine actionable insight — an evidence gap with implications for medical strategy. Record it in the structured system; it is not something to respond to with a slide.
6. Refuse, and explain why. The scientific deck contains balance, limitations and possibly reactive content that promotional use rules do not permit. This is the direction the boundary leaks most often, and the request is usually made in good faith.
The pattern: six requests, six different materials, and in four of them the tempting wrong answer is a material that exists and is approved — just not for that purpose. Approval is always for something.
2. A licensed reprint of the publication. Check the licence covers this use and this market. Not a PDF downloaded and forwarded without a licence — that is a copyright issue on top of everything else.
3. The medical information process. Not the field deck, and not the FAQ document unless it contains designated reactive-only content and the question was genuinely unsolicited.
4. Advisory board materials, with a defined advisory question and documented expertise-based selection. Not a meeting convened to present data to influential clinicians — that is a promotional activity wearing an advisory board's clothes.
5. Insight capture. This is a genuine actionable insight — an evidence gap with implications for medical strategy. Record it in the structured system; it is not something to respond to with a slide.
6. Refuse, and explain why. The scientific deck contains balance, limitations and possibly reactive content that promotional use rules do not permit. This is the direction the boundary leaks most often, and the request is usually made in good faith.
The pattern: six requests, six different materials, and in four of them the tempting wrong answer is a material that exists and is approved — just not for that purpose. Approval is always for something.
Reflection
In an organisation you know, is the boundary between medical and commercial materials clear in practice, or only on paper?
Next module
1.4 — Surviving MLR review
Week 1 · Module 4
Surviving MLR review
Three reviewers assessing three different things. Understanding what each is looking for turns four review rounds into two
Your scenario
The deck comes back from review with 47 comments. Most are the same three problems repeated across slides: an unreferenced claim, a favourable adjective, and a figure whose limitations are missing. All three were avoidable before submission, and fixing them once at the start would have removed most of the 47.
Three lenses
Figure 1.4 — The three lenses. Reviewers are not applying one standard from three desks; they are applying three different standards. Writing for all three from the first draft is what turns a four-round review into a two-round one.
Pre-empting the three recurring faults
| Fault | Fix before submission | Check |
|---|---|---|
| Unreferenced claim | Every data point carries a citation to a publication or the label | Read the deck ignoring the data; every remaining assertion needs a source |
| Favourable adjective | Delete or replace with the number | Search for well, only, clearly, importantly, favourable, promising, robust |
| Missing limitation | Every efficacy claim carries the qualifier its design requires | Subgroup slides, immature endpoints, single-arm data, post-hoc analyses |
| Cross-trial comparison | Remove, or state that no head-to-head data exist | Any slide showing two products' numbers, even without a stated comparison |
| Off-label content | Remove from proactive material entirely | Check the local label, not the global one |
| Missing front matter | Intended use, audience, non-promotional designation, version and date | First slide, every time |
Respond to review comments like a reviewer response letter
Quote the comment, state what you changed and where, or explain with evidence why you disagree — and change the slide anyway so the next reviewer does not raise the same point.
Never leave a comment unanswered, and never make a change you did not tell the reviewer about. Both add a round.
Never leave a comment unanswered, and never make a change you did not tell the reviewer about. Both add a round.
Drills
Drill 1 of 3
A slide is scientifically accurate, fully referenced, and shows an unapproved indication. Which reviewer rejects it?
AMedical
BLegal
CRegulatory
DNone — it would clear
Drill 2 of 3
A reviewer writes "unbalanced" against a subgroup slide. What is the likely fix?
ADelete the slide
BAdd more supportive data
CAdd a general disclaimer at the end of the deck
DAdd the design qualifier and the interaction test, and show all prespecified subgroups
Drill 3 of 3
You disagree with a review comment. What do you do?
ARespond with evidence, and clarify the slide so the point cannot recur
BLeave it unaddressed and resubmit
CChange it without comment
DEscalate to the reviewer’s manager
Production drill
Predict the MLR comments on each slide, by reviewer, and fix each one.
Slide A: Title "Robust efficacy across the population". Forest plot of 11 subgroups. No interaction p values shown. No reference.
Slide B: Title "Favourable tolerability profile". Bar chart of grade ≥3 events for your product (37.8%) and, beside it, a competitor's published rate (41%). Both referenced.
Slide C: Title "Extending benefit to earlier lines". Phase II data in first-line use. Product approved second line only. Fully referenced, accurate.
Slide B: Title "Favourable tolerability profile". Bar chart of grade ≥3 events for your product (37.8%) and, beside it, a competitor's published rate (41%). Both referenced.
Slide C: Title "Extending benefit to earlier lines". Phase II data in first-line use. Product approved second line only. Fully referenced, accurate.
Slide A
Medical: “Robust” is an unreferenced favourable characterisation → retitle to state the finding, e.g. “Treatment effect was consistent across prespecified subgroups”. Also: 11 subgroups shown where six were prespecified → show the six, label the rest exploratory or remove. No interaction p values → add them; without them the plot invites comparison of rows, which is invalid.
Legal / Regulatory: no reference → add the citation.
Slide B
Medical: “Favourable” is a judgement → retitle to the numbers. And the two rates come from different trials with different populations and reporting conventions → the comparison is scientifically invalid.
Legal / Regulatory: this is a comparative claim with no head-to-head data, made by juxtaposition rather than by sentence — which is still a claim. Remove the competitor bar entirely. Show your product's rate against its own trial comparator, and if comparison is raised, state that no head-to-head data exist.
Slide C
Regulatory: first-line use is outside the approved indication. Accurate, referenced and Phase II does not change that — off-label content cannot appear in proactive field material. Remove the slide. The title alone, “Extending benefit to earlier lines”, is promotion of an unapproved use.
Medical: separately, single-arm Phase II data presented without the design limitation would fail balance even if the indication were approved.
The escalation across the three: Slide A needs rewriting. Slide B needs an element removed. Slide C cannot be fixed and must go. Recognising which category a problem falls into — rewrite, trim, or delete — before submission is what separates a two-round review from a four-round one.
Medical: “Robust” is an unreferenced favourable characterisation → retitle to state the finding, e.g. “Treatment effect was consistent across prespecified subgroups”. Also: 11 subgroups shown where six were prespecified → show the six, label the rest exploratory or remove. No interaction p values → add them; without them the plot invites comparison of rows, which is invalid.
Legal / Regulatory: no reference → add the citation.
Slide B
Medical: “Favourable” is a judgement → retitle to the numbers. And the two rates come from different trials with different populations and reporting conventions → the comparison is scientifically invalid.
Legal / Regulatory: this is a comparative claim with no head-to-head data, made by juxtaposition rather than by sentence — which is still a claim. Remove the competitor bar entirely. Show your product's rate against its own trial comparator, and if comparison is raised, state that no head-to-head data exist.
Slide C
Regulatory: first-line use is outside the approved indication. Accurate, referenced and Phase II does not change that — off-label content cannot appear in proactive field material. Remove the slide. The title alone, “Extending benefit to earlier lines”, is promotion of an unapproved use.
Medical: separately, single-arm Phase II data presented without the design limitation would fail balance even if the indication were approved.
The escalation across the three: Slide A needs rewriting. Slide B needs an element removed. Slide C cannot be fixed and must go. Recognising which category a problem falls into — rewrite, trim, or delete — before submission is what separates a two-round review from a four-round one.
Reflection
Think of review comments you have received. How many were the same three faults repeated?
Next week
2.1 — Deck architecture for field use
Week 2 · Module 1
Deck architecture for field use
A deck that supports dialogue rather than delivering a message — modular, navigable, and built to be entered at any point
Your scenario
The deck is 60 slides in a fixed narrative order. A clinician asks about safety in renal impairment four minutes into the meeting. You are scrolling through forty slides to find it while they wait — and the deck's structure has just made you look unprepared in a meeting you prepared for.
A field deck is not a presentation
| Congress presentation | Field medical deck |
|---|---|
| Linear, one narrative, fixed order | Modular — sections entered in any order the conversation takes |
| Ten minutes, uninterrupted | Dialogue, interrupted constantly, often 15–20 minutes total |
| One audience, one time | Many audiences, many times, by many people |
| Presenter knows the material intimately | Used by colleagues who did not build it |
| Backup slides for questions | Most of the deck is effectively backup; you show what is asked about |
Structure for navigation
Build a contents slide with hyperlinks to each section, and a return link on every section divider. In a live meeting, one click to safety data is the difference between a conversation and an apology.
Sections should be self-contained: a clinician who only sees the safety module should still get referenced, balanced information with its limitations.
Sections should be self-contained: a clinician who only sees the safety module should still get referenced, balanced information with its limitations.
Front matter
| Element | Why |
|---|---|
| Intended use statement | What the deck is for and how it may be used |
| Intended audience | Healthcare professionals; often region-specific |
| Non-promotional designation | States explicitly that this is scientific information, not promotion |
| Approved indication | So every subsequent slide is read against it |
| Version, date, approval code | Reconstructing what was in use on a given date |
| Abbreviations | The deck may be entered at any slide |
Drills
Drill 1 of 3
Why should a field deck be modular rather than linear?
AIt reduces the number of slides
BThe conversation dictates the order, so any section must be reachable directly
CIt speeds up MLR review
DIt is a regulatory requirement
Drill 2 of 3
What must the first slide of a field deck contain?
AThe headline efficacy result
BThe product logo and tagline
CIntended use, audience, non-promotional designation, indication, version and date
DThe contents page only
Drill 3 of 3
A section of the deck will sometimes be shown alone. What follows?
ANothing — the rest of the deck provides context
BSections should never be shown alone
CAdd a disclaimer at the end of the deck
DEach section must be balanced and referenced on its own
Production drill
Design the deck structure. Name the sections and specify the front matter.
Product: approved second-line advanced disease. Pivotal Phase III plus a published real-world cohort and a dedicated renal impairment PK study.
Typical questions from clinicians: efficacy magnitude; how it works; safety and monitoring; use in renal and hepatic impairment; use in older patients; how it fits with existing therapy; what the real-world data show.
Constraint: the deck is used by 14 colleagues across 6 countries.
Typical questions from clinicians: efficacy magnitude; how it works; safety and monitoring; use in renal and hepatic impairment; use in older patients; how it fits with existing therapy; what the real-world data show.
Constraint: the deck is used by 14 colleagues across 6 countries.
Front matter (slides 1–3)
1. Title, intended use, intended audience, non-promotional designation, version, date, approval code.
2. Approved indication as licensed, with a note that indications may differ by country and that the local label applies. Essential here — 6 countries means 6 labels.
3. Contents, hyperlinked to each section.
Sections, each self-contained with its own references and limitations:
A. Disease and treatment context — the clinical problem, without product content
B. Mechanism of action
C. Pivotal trial: design — including the endpoint hierarchy
D. Pivotal trial: efficacy — primary, then secondary with hierarchy status stated
E. Pivotal trial: safety
F. Special populations — renal, hepatic, older patients; the PK study lives here
G. Real-world evidence — with observational design limitations stated on the section’s own slides
H. Practical use — dosing, monitoring, modifications, all from the label
I. References
J. Backup — full tables, subgroup detail, methodology
Three design decisions:
1. Section A carries no product content. It lets a conversation start scientifically rather than with the product, which is what exchange looks like.
2. Section G states its own limitations on its own slides. If a clinician only sees the real-world module, the observational caveats must be in front of them — they cannot live in section C.
3. Slide 2 flags that indications differ by country. With 14 users across 6 markets, a deck that implies one indication will be used in a market where it is wrong.
The multi-market problem: a single global deck used in 6 countries either needs local adaptation before use or a clear instruction that the local label governs. Do not leave 14 colleagues to work that out individually.
1. Title, intended use, intended audience, non-promotional designation, version, date, approval code.
2. Approved indication as licensed, with a note that indications may differ by country and that the local label applies. Essential here — 6 countries means 6 labels.
3. Contents, hyperlinked to each section.
Sections, each self-contained with its own references and limitations:
A. Disease and treatment context — the clinical problem, without product content
B. Mechanism of action
C. Pivotal trial: design — including the endpoint hierarchy
D. Pivotal trial: efficacy — primary, then secondary with hierarchy status stated
E. Pivotal trial: safety
F. Special populations — renal, hepatic, older patients; the PK study lives here
G. Real-world evidence — with observational design limitations stated on the section’s own slides
H. Practical use — dosing, monitoring, modifications, all from the label
I. References
J. Backup — full tables, subgroup detail, methodology
Three design decisions:
1. Section A carries no product content. It lets a conversation start scientifically rather than with the product, which is what exchange looks like.
2. Section G states its own limitations on its own slides. If a clinician only sees the real-world module, the observational caveats must be in front of them — they cannot live in section C.
3. Slide 2 flags that indications differ by country. With 14 users across 6 markets, a deck that implies one indication will be used in a market where it is wrong.
The multi-market problem: a single global deck used in 6 countries either needs local adaptation before use or a clear instruction that the local label governs. Do not leave 14 colleagues to work that out individually.
Reflection
Take a deck you have used. Could a colleague find the safety section in one click?
Next module
2.2 — Referencing every claim
Week 2 · Module 2
Referencing every claim
Every statement traceable to something the audience could obtain — and the checks that stop a deck citing superseded data
Your scenario
A deck slide cites a congress abstract from three years ago. The full publication appeared eighteen months later with a different median and a wider interval. The deck has been presenting superseded data for a year and a half, to clinicians who reasonably assumed it was current.
The rules
| Rule | Why |
|---|---|
| Every data point carries a reference | Unreferenced claims do not survive MLR and cannot be defended |
| References point to obtainable sources | An internal table number is unverifiable by the audience |
| Label citations give section and version | Labels change; the version fixes what was true |
| Abstracts identified as abstracts | Preliminary data may have been superseded |
| Nothing cited that the builder has not read | Citing from a secondary summary propagates errors |
| Reference list matches the slides exactly | Orphan references and missing citations are both MLR findings |
The refresh check
At every deck update, run three checks on the reference list:
1. Has any cited abstract become a full publication? If so, switch to the publication and check the numbers changed.
2. Has the label changed? Every label citation needs its version re-verified.
3. Has any cited study been retracted, corrected or superseded? Corrections in particular are easy to miss and change specific figures.
Twenty minutes per refresh, and it is the difference between a current deck and one that has been quietly wrong for a year.
1. Has any cited abstract become a full publication? If so, switch to the publication and check the numbers changed.
2. Has the label changed? Every label citation needs its version re-verified.
3. Has any cited study been retracted, corrected or superseded? Corrections in particular are easy to miss and change specific figures.
Twenty minutes per refresh, and it is the difference between a current deck and one that has been quietly wrong for a year.
Drills
Drill 1 of 3
A slide references "Internal analysis, Table 14.2.1". Acceptable?
ANo — use data on file with a proper identifier, or a publication
BYes — it is fully traceable
CYes, if the statistician approved it
DYes, for specialist audiences
Drill 2 of 3
At deck refresh, you find a cited abstract now has a full publication with slightly different numbers. What do you do?
AKeep the abstract — its numbers are better
BSwitch to the publication and update the figures
CCite both
DNote it for the next refresh
Drill 3 of 3
How should a label be cited on a field slide?
A“[Product] label”
BNo citation needed for label content
C“[Product] [SmPC/USPI], [market], section [x], version [date]”
DCite the company core data sheet
Production drill
Audit this reference list against the slides. List every problem.
Slides state:
1. "Approved for second-line use" — no citation
2. "Median PFS 8.9 vs 5.2 months" — ref 1
3. "Reduce dose in moderate renal impairment" — ref 1
4. "Real-world response rate 39%" — ref 2
5. "Grade ≥3 events 37.8%" — ref 3
6. "Well established in clinical practice" — no citation
Reference list:
1. [Pivotal trial publication], 2023
2. [Congress abstract], 2022
3. Data on file
4. [Review article], 2021 — not cited on any slide
1. "Approved for second-line use" — no citation
2. "Median PFS 8.9 vs 5.2 months" — ref 1
3. "Reduce dose in moderate renal impairment" — ref 1
4. "Real-world response rate 39%" — ref 2
5. "Grade ≥3 events 37.8%" — ref 3
6. "Well established in clinical practice" — no citation
Reference list:
1. [Pivotal trial publication], 2023
2. [Congress abstract], 2022
3. Data on file
4. [Review article], 2021 — not cited on any slide
Seven problems:
1. Slide 1 unreferenced. The approved indication must cite the label with market, section and version.
2. Slide 3 cites the trial publication for a dosing recommendation. Wrong source — dose adjustment in renal impairment is a labelling matter. Cite the label, section 4.2.
3. Slide 4 cites a congress abstract from 2022. Check whether a full publication has appeared; if so, switch and re-check the number. Also identify it as an abstract on the slide.
4. Slide 5 cites data on file for grade ≥3 events — but that figure is in the pivotal publication (ref 1). Data on file must not be used where a published source exists.
5. Slide 6 is unreferenced and unreferenceable. “Well established in clinical practice” is a favourable characterisation, not a fact. Delete it or replace with the approval date and a specific guideline citation.
6. Reference 4 is an orphan — in the list, cited nowhere. Remove it, or find the slide that lost its citation.
7. No label reference appears anywhere in the list, despite two slides making label claims. This is the structural finding: the deck cites trials but not the document that governs approved use.
The two that would fail MLR outright: problem 5, because it is an unreferenced promotional claim; and problem 4, because using data on file when published data exist looks like source-shopping even when it is only carelessness.
1. Slide 1 unreferenced. The approved indication must cite the label with market, section and version.
2. Slide 3 cites the trial publication for a dosing recommendation. Wrong source — dose adjustment in renal impairment is a labelling matter. Cite the label, section 4.2.
3. Slide 4 cites a congress abstract from 2022. Check whether a full publication has appeared; if so, switch and re-check the number. Also identify it as an abstract on the slide.
4. Slide 5 cites data on file for grade ≥3 events — but that figure is in the pivotal publication (ref 1). Data on file must not be used where a published source exists.
5. Slide 6 is unreferenced and unreferenceable. “Well established in clinical practice” is a favourable characterisation, not a fact. Delete it or replace with the approval date and a specific guideline citation.
6. Reference 4 is an orphan — in the list, cited nowhere. Remove it, or find the slide that lost its citation.
7. No label reference appears anywhere in the list, despite two slides making label claims. This is the structural finding: the deck cites trials but not the document that governs approved use.
The two that would fail MLR outright: problem 5, because it is an unreferenced promotional claim; and problem 4, because using data on file when published data exist looks like source-shopping even when it is only carelessness.
Reflection
When was the last deck you used checked for superseded abstracts?
Next module
2.3 — Digital Field Tools, iDVAs & Modular Content
Week 2 · Module 3
Digital Field Tools, iDVAs & Modular Content
Designing interactive digital visual aids (iDVAs), Veeva CRM/CLM multichannel modules, and compliant non-linear dialogue flows
Your scenario
Your global Medical Affairs team is modernizing its field deployment by converting a 160-slide static PowerPoint into a Veeva CRM-compliant Interactive Digital Visual Aid (iDVA) for MSL iPad interactions. The brand commercial team requests that you embed auto-calculating health-economic ROI calculators and pre-set mandatory slide sequences that every MSL must click through. You must explain why rigid linear sequencing violates non-promotional scientific exchange, and architect a modular, reactive digital branching model that complies with medical governance while capturing audit metrics.
Modern field medical interactions have shifted decisively from static, linear slide presentations to Interactive Digital Visual Aids (iDVAs) deployed via multichannel Customer Relationship Management platforms (such as Veeva CLM, Salesforce Life Sciences Cloud, or OCE). In a digital environment, the medical writer is not merely a content drafter, but an information architect who structures clinical evidence for flexible, clinician-directed exploration.
The primary hazard in digital medical material design is the temptation to replicate commercial sales aids. Commercial digital visual aids use structured call-to-actions, forced click-through funnels, and prescriptive messaging tracks. In contrast, a medical iDVA is an interactive scientific reference library: it must allow the Healthcare Professional (HCP) to steer the scientific dialogue organically, moving freely between mechanistic animations, subgroup analyses, safety tables, and study methodologies without being subjected to a scripted marketing pitch.
Digital Governance Digital Medical Content Architecture: Static Slide Deck vs. Modular iDVA in Veeva CRM
Field medical writers must structure digital assets to ensure non-promotional flexibility while satisfying strict regulatory audit logging requirements:
| Architectural Dimension | Legacy Static Slide Deck (PowerPoint / PDF) | Modular Medical iDVA (Veeva CRM / CLM) | Medical Writer Compliance Standard |
|---|---|---|---|
| Navigation Model | Linear (Slide 1 → 2 → 3); forces chronological traversal of sponsor story. | Non-linear, hub-and-spoke branching; HCP chooses which scientific node to open. | Mandatory interactive table-of-contents hub; no forced forward-progression locks or auto-advancing slides. |
| Content Granularity | Monolithic presentation file (80–150 slides) approved as a single asset. | Discrete, pre-approved modular blocks (claims, data graphs, study designs) assembled dynamically. | Each digital module must carry independent front-matter context, trial caveats, and full citation footnotes. |
| Digital Audit & Analytics | No interaction logging; binary delivery record (deck presented: Yes/No). | Granular time-on-screen metrics, node activation logging, asset click-through trails. | Interaction tracking must record scientific discussion topics without capturing Protected Health Information (PHI). |
| Content Expiry & Refresh | Manual replacement; superseded decks frequently linger on field laptops. | Automated cloud push-sync with centralized auto-expiration and instant recall. | Establish digital expiration metadata (e.g., 12-month re-certification limit or instant update on label change). |
The 3-Layer iDVA Architecture
To ensure compliant and agile scientific dialogue, professional medical writers architect field iDVAs using a 3-tier hierarchical structure:
- Layer 1: The Master Interactive Hub (Overview Screen): High-level visual overview of the clinical program (e.g., Disease Burden, Mechanism of Action, Pivotal Trial Schema, Safety Profile, Real-World Evidence). From here, the MSL can tap directly to any domain based on the clinician's inquiry.
- Layer 2: Core Evidence Cards: The primary study findings presented objectively (e.g., Kaplan-Meier curves with confidence intervals, hazard ratios, Forest plots, and primary safety tables).
- Layer 3: Deep-Dive Sub-Modals (Reactive Drill-Downs): Granular methodological details, pharmacokinetic sub-studies, baseline demographic breakdowns, and statistical interaction tests accessed only when specifically requested by the HCP.
Drills
Drill 1 of 3
A digital agency designing a medical iDVA includes a mandatory 'next slide' button lock, requiring the MSL to click through efficacy slides before unlocking the safety tab. What is the compliance issue?
ANo issue — it guarantees the HCP views all foundational evidence in order
BOnly an issue if the tablet operating system crashes during transit
CForced sequential progression violates non-promotional principles; navigation must be non-linear and clinician-directed
DAcceptable provided the safety tab is eventually visited
Drill 2 of 3
When authoring modular content blocks for a Veeva CLM digital library, what must each individual modular slide contain?
AOnly the data graph; context can be assumed from whichever screen was opened previously
BA prominent commercial brand tagline and product logo in the header
CA QR code linking to an external website without any on-screen footnotes
DStand-alone contextual balance, primary study citations, sample sizes (N), and relevant safety caveats
Drill 3 of 3
Which digital analytics metric is appropriate for Medical Affairs leadership to track in Veeva CRM?
AAggregated dwell time on scientific topics and frequency of deep-dive modal requests
BCorrelation between slide views and immediate post-visit prescription spikes
CIndividual patient names and clinical notes entered during the consultation
DMSL ranking based on number of HCPs converted to active brand advocates
Production drill
Audit this digital iDVA wireframe proposal from an external medical agency and identify all compliance and architectural defects.
Agency iDVA Proposal (iPad Application for Field MSLs):
Screen 1 (Splash Page): Prominent brand hero graphic, approved brand slogan ("The New Standard of Care in RCC"), and a 'Start Interactive Journey' button.
Screen 2 (Mandatory Funnel): Animated video showing superior drug binding affinity vs. competitor molecule X. User cannot swipe or tap menu until 60-second video finishes playing.
Screen 3 (Efficacy Dashboard): Primary endpoint PFS curve (p<0.001). No confidence intervals shown on graph to keep UI 'clean and uncluttered'. Footnote states: 'Refer to Master Module for study details.'
Screen 4 (Interactive ROI Tool): HCP enters their hospital patient volume; calculator automatically projects annual departmental cost savings when switching from competitor therapy.
Screen 5 (Safety Summary): Bulleted text: 'Well-tolerated with manageable adverse events.' Full safety table placed in an external PDF link that requires internet connectivity.
Screen 1 (Splash Page): Prominent brand hero graphic, approved brand slogan ("The New Standard of Care in RCC"), and a 'Start Interactive Journey' button.
Screen 2 (Mandatory Funnel): Animated video showing superior drug binding affinity vs. competitor molecule X. User cannot swipe or tap menu until 60-second video finishes playing.
Screen 3 (Efficacy Dashboard): Primary endpoint PFS curve (p<0.001). No confidence intervals shown on graph to keep UI 'clean and uncluttered'. Footnote states: 'Refer to Master Module for study details.'
Screen 4 (Interactive ROI Tool): HCP enters their hospital patient volume; calculator automatically projects annual departmental cost savings when switching from competitor therapy.
Screen 5 (Safety Summary): Bulleted text: 'Well-tolerated with manageable adverse events.' Full safety table placed in an external PDF link that requires internet connectivity.
Defects Identified & Medical Writer Corrections:
1. Promotional Slogan on Screen 1: "The New Standard of Care" is a promotional claim that violates non-promotional medical exchange. Fix: Replace with objective front matter: study title, approved non-proprietary compound name, target audience, and non-promotional designation.
2. Mandatory Progression Lock & Competitor Comparison on Screen 2: Forced video view violates clinician-directed navigation. Furthermore, head-to-head mechanistic comparison without robust randomized trial evidence constitutes ungrounded competitor disparagement. Fix: Make video optional via a pop-up modal; remove competitor comparison.
3. Omitted Confidence Intervals & Deferred Citations on Screen 3: Deleting CIs for 'clean UI' distorts statistical validity. In modular CLM architectures, every screen must be self-contained. Fix: Add 95% CIs, Hazard Ratios (HR), numbers at risk, and complete primary publication citation directly on the screen.
4. Interactive Cost/ROI Calculator on Screen 4: Commercial pricing, hospital formulary budgets, and departmental ROI calculations are commercial/market access domains outside the MSL scientific exchange remit. Fix: Delete Screen 4 entirely from the medical iDVA.
5. Superficial Safety & Dependent Connectivity on Screen 5: "Well-tolerated" is subjective editorializing. Putting safety tables behind an online link violates the requirement for on-demand offline fair balance. Fix: Embed comprehensive Grade 3/4 TEAE tables, discontinuations, and dose modifications directly within local offline app storage.
1. Promotional Slogan on Screen 1: "The New Standard of Care" is a promotional claim that violates non-promotional medical exchange. Fix: Replace with objective front matter: study title, approved non-proprietary compound name, target audience, and non-promotional designation.
2. Mandatory Progression Lock & Competitor Comparison on Screen 2: Forced video view violates clinician-directed navigation. Furthermore, head-to-head mechanistic comparison without robust randomized trial evidence constitutes ungrounded competitor disparagement. Fix: Make video optional via a pop-up modal; remove competitor comparison.
3. Omitted Confidence Intervals & Deferred Citations on Screen 3: Deleting CIs for 'clean UI' distorts statistical validity. In modular CLM architectures, every screen must be self-contained. Fix: Add 95% CIs, Hazard Ratios (HR), numbers at risk, and complete primary publication citation directly on the screen.
4. Interactive Cost/ROI Calculator on Screen 4: Commercial pricing, hospital formulary budgets, and departmental ROI calculations are commercial/market access domains outside the MSL scientific exchange remit. Fix: Delete Screen 4 entirely from the medical iDVA.
5. Superficial Safety & Dependent Connectivity on Screen 5: "Well-tolerated" is subjective editorializing. Putting safety tables behind an online link violates the requirement for on-demand offline fair balance. Fix: Embed comprehensive Grade 3/4 TEAE tables, discontinuations, and dose modifications directly within local offline app storage.
Reflection
When transitioning print or slide materials to digital tablets, how do you prevent interactive features from becoming commercial sales gadgets?
Next module
2.4 — Data on file and unapproved content
Week 2 · Module 4
Data on file and unapproved content
Where the boundary is sharpest: unpublished data, off-label uses and pipeline compounds in a proactive material
Your scenario
A slide summarises a published Phase II study in an indication the product is not approved for. Accurate, peer-reviewed, fully referenced. It is in a deck that will be carried into meetings and shown. Publication does not make an unapproved use presentable in proactive material.
Three categories that behave differently
| Category | In a proactive field deck | Reactively, on unsolicited request |
|---|---|---|
| Approved use, published | Yes, referenced and balanced | Yes |
| Approved use, unpublished | Data on file, only if no published source exists | Yes, same conditions |
| Off-label use, published | No — publication does not make it presentable proactively | Yes, via the medical information process |
| Pipeline compound | No | Only publicly disclosed registry information |
| Comparative, no head-to-head | No — including by juxtaposition | State that no head-to-head data exist |
The distinction people collapse
Published is not the same as approved, and accurate is not the same as permissible.
A Phase II study of an unapproved indication can be discussed with a clinician who asks about it, through the medical information process, with the unapproved status stated. It cannot sit in a deck you carry into meetings — because that deck is proactive by construction, and showing the slide is volunteering the content.
A Phase II study of an unapproved indication can be discussed with a clinician who asks about it, through the medical information process, with the unapproved status stated. It cannot sit in a deck you carry into meetings — because that deck is proactive by construction, and showing the slide is volunteering the content.
Data on file, properly
| Required | Never acceptable |
|---|---|
| No published source exists for that question | Using it because it is more favourable than the published source |
| Underlying analysis retained and retrievable | Referencing it by internal table number |
| Unique identifier on the slide | Presenting it as though published |
| Approved through the normal process | Supporting a claim published data do not carry |
| Labelled clearly as unpublished company data | Adding it after MLR approval |
Drills
Drill 1 of 3
A peer-reviewed Phase II study of an unapproved indication. May it appear in a field deck?
AYes — it is peer-reviewed
BYes, with a disclaimer
CNo — a carried deck is proactive; handle it reactively instead
DYes, if placed in the backup section
Drill 2 of 3
A published figure and an internal analysis both answer the question. The internal one is more favourable. Which goes in the deck?
AThe internal analysis, as data on file
BBoth, side by side
CWhichever is more recent
DThe published figure
Drill 3 of 3
A slide shows your product's grade ≥3 rate beside a competitor's published rate, with no comparison stated. Acceptable?
ANo — juxtaposition is itself a comparative claim
BYes — both figures are referenced
CYes, with a footnote about different populations
DYes, if the competitor’s rate is lower
Production drill
Decide what stays in the proactive deck, what moves to reactive handling, and what goes entirely.
Proposed content:
1. Pivotal Phase III efficacy — approved indication, published
2. Real-world cohort — approved indication, published, observational
3. Phase II in first line — not approved, published
4. Pooled safety across three trials — approved indication, unpublished internal analysis
5. Next-generation compound in Phase III — registered, no published data
6. Bar chart of your grade ≥3 rate beside a competitor's
7. Dose adjustment in renal impairment — from the label
8. Investigator-initiated study in an unapproved population — published
1. Pivotal Phase III efficacy — approved indication, published
2. Real-world cohort — approved indication, published, observational
3. Phase II in first line — not approved, published
4. Pooled safety across three trials — approved indication, unpublished internal analysis
5. Next-generation compound in Phase III — registered, no published data
6. Bar chart of your grade ≥3 rate beside a competitor's
7. Dose adjustment in renal impairment — from the label
8. Investigator-initiated study in an unapproved population — published
Stays in the proactive deck:
1. Pivotal efficacy — approved, published, referenced, with hierarchy status stated.
2. Real-world cohort — approved indication, published. Must carry its observational limitations on its own slides: association not causation, unmeasured confounding.
4. Pooled safety — only if no published pooled analysis exists. As data on file with an identifier, retained and retrievable. Check for a published source first.
7. Renal dosing — from the label, cited with market, section and version.
Moves to reactive handling via medical information:
3. Phase II first line — published but off-label. Answerable on unsolicited request, not presentable proactively.
8. Investigator-initiated study in an unapproved population — same reasoning. Being investigator-initiated does not change its off-label status.
5. Pipeline compound — reactively, only confirmation of publicly registered trial information. No efficacy, no safety, no timing.
Out entirely:
6. The competitor bar chart. Cross-trial comparison, invalid regardless of which way it points, and a comparative claim by juxtaposition. There is no version of this slide that survives.
The four-way split: half the proposed content stays, three items become reactive-only, and one cannot exist in any form. Item 8 is the one most often mishandled — investigator-initiated feels arm's-length, and it makes no difference to whether the use is approved.
1. Pivotal efficacy — approved, published, referenced, with hierarchy status stated.
2. Real-world cohort — approved indication, published. Must carry its observational limitations on its own slides: association not causation, unmeasured confounding.
4. Pooled safety — only if no published pooled analysis exists. As data on file with an identifier, retained and retrievable. Check for a published source first.
7. Renal dosing — from the label, cited with market, section and version.
Moves to reactive handling via medical information:
3. Phase II first line — published but off-label. Answerable on unsolicited request, not presentable proactively.
8. Investigator-initiated study in an unapproved population — same reasoning. Being investigator-initiated does not change its off-label status.
5. Pipeline compound — reactively, only confirmation of publicly registered trial information. No efficacy, no safety, no timing.
Out entirely:
6. The competitor bar chart. Cross-trial comparison, invalid regardless of which way it points, and a comparative claim by juxtaposition. There is no version of this slide that survives.
The four-way split: half the proposed content stays, three items become reactive-only, and one cannot exist in any form. Item 8 is the one most often mishandled — investigator-initiated feels arm's-length, and it makes no difference to whether the use is approved.
Reflection
Have you seen a slide that placed two products' numbers side by side without stating a comparison? Did it read as a comparison?
Next module
3.1 — Key Opinion Leader (KOL) Mapping & SEPs
Week 3 · Module 1
Key Opinion Leader (KOL) Mapping & Scientific Engagement Plans
Establishing objective thought-leader tiering criteria, institutional influence mapping, and compliant annual Scientific Engagement Plans (SEPs)
Your scenario
As a Medical Affairs lead in hematology, you are tasked with creating the annual Scientific Engagement Plan (SEP) for 75 Key Opinion Leaders (KOLs) across the territory. The commercial marketing director provides a spreadsheet of the top 30 prescribing hematologists and asks you to prioritize weekly MSL visits to ensure they adopt the newly launched CAR-T therapy. You must reject commercial prescriber lists, establish an objective, research-based KOL tiering methodology, and draft compliant SEPs focused on educational evidence gaps and clinical research collaborations.
Key Opinion Leaders (KOLs) — also referred to as External Experts (EEs), Thought Leaders (TLs), or Key Medical Experts (KMEs) — are leading clinicians and researchers whose clinical experience, scientific publications, and guideline committee memberships shape medical practice. In Medical Affairs, engaging with KOLs is essential for understanding real-world clinical practice, gathering strategic scientific insights, and identifying evidence gaps.
However, KOL engagement is heavily scrutinized by regulatory authorities and compliance auditors (including the US OIG, DOJ, and EU national health authorities). Under global compliance codes, pharmaceutical companies are strictly prohibited from selecting, tiering, or compensating KOLs based on their prescribing volume, formulary influence, or commercial value. All thought-leader mapping must be grounded in verifiable scientific merit, academic scholarship, and clinical research credentials.
Strategic Matrix The 3-Tier Thought Leader Classification & Engagement Rubric
Medical Affairs categorizes external experts using objective scientific parameters to align compliant engagement cadences:
| Expert Tier | Objective Profiling & Qualification Criteria | Primary Medical Affairs Activities | Compliant Touchpoint Cadence |
|---|---|---|---|
| Tier 1: Global / National Academic Leaders | International trial Principal Investigators (PIs), clinical practice guideline authors (e.g. NCCN, ESMO, ACC), journal editorial board members, seminal peer-reviewed lead authors. | Global Advisory Board chairs, steering committee leadership, clinical trial protocol co-design, plenary symposium faculty. | Strategic touchpoints (2–4 annual milestone meetings, congress engagements, ad boards); strictly driven by scientific project needs. |
| Tier 2: Regional Medical Experts | Regional hospital department chairs, prominent sub-specialty referral center leads, regional congress presenters, active clinical trial co-investigators. | Regional ad boards, educational case-study development, local speaker training (non-promotional), regional clinical data dissemination. | Quarterly scientific exchanges (3–6 visits/year) focused on regional standard-of-care challenges and diagnostic protocols. |
| Tier 3: Community Key Clinicians | High-volume institutional community practitioners, local multidisciplinary team (MDT) leaders, community clinical trial site coordinators. | Community practice insights, identification of real-world implementation hurdles, medical education roundtables. | Bi-annual or reactive interactions (2–4 visits/year) addressing specific scientific inquiries and local educational initiatives. |
Anatomy of a Scientific Engagement Plan (SEP)
A Scientific Engagement Plan (SEP) is a personalized, living strategic document created for each prioritized external expert. It outlines the scientific objectives of the relationship for the calendar year. A compliant SEP contains 5 core components:
- Expert Scientific Profile: Focus of academic research, ongoing clinical trials, clinical interests, key publications, and therapeutic philosophy.
- Current Scientific Baseline & Unmet Needs: The expert's perspective on disease pathophysiology, existing therapeutic limitations, and evidence gaps.
- Annual Medical Objectives: Defined scientific collaboration goals (e.g., advising on registry protocol design, providing feedback on real-world toxicity management).
- Planned Scientific Touchpoints: Concrete milestone events (e.g., ASCO congress discussion, Q3 Advisory Board, Q4 investigator meeting).
- Strategic Insight Themes: Specific questions to explore during interactions (e.g., institutional barriers to biomarker turnaround times).
Drills
Drill 1 of 3
Which metric is legally permissible when establishing KOL tiering criteria in Medical Affairs?
AAnnual retail and hospital prescription volume for the disease indication
BNumber of peer-reviewed publications, clinical trial PI experience, and guideline panel appointments
CWillingness of the clinician to advocate for the brand in commercial sales meetings
DCommercial influence over the hospital formulary tender award process
Drill 2 of 3
What constitutes an appropriate medical objective within an individual Scientific Engagement Plan (SEP)?
AConvert the clinician from prescribing competitor drug Y to our product by Q3
BPersuade the clinician to submit a hospital formulary addition request for the drug
CEngage expert in exploring diagnostic algorithms for early detection of immune-mediated myocarditis
DEstablish a commitment for the clinician to initiate 10 new patients on therapy this year
Drill 3 of 3
How should a medical writer evaluate the performance and value of field MSL thought-leader interactions?
ABy tracking the sales revenue growth in the MSL's designated geographic territory
BBy the sheer raw number of coffee meetings conducted, regardless of scientific purpose
CBy the percentage of visited clinicians who agreed with the commercial brand positioning
DBy assessing the strategic quality of captured insights and completion of planned scientific milestone activities
Production drill
Convert this commercially contaminated 'KOL Profile & Plan' into a compliant Medical Affairs Scientific Engagement Plan (SEP).
Draft Thought Leader Profile: Dr. Marcus Vance (Chief of Neuro-Oncology)
Commercial Tier: Gold Tier ($1.2M annual territory prescription potential).
Commercial Goal: Flip Dr. Vance from prescribing standard-of-care temozolomide to our novel kinase inhibitor by Q4.
Tactical Plan:
· Visit Dr. Vance fortnightly with high-impact sales messaging on PFS superiority.
· Offer him a paid speaker contract on the commercial tour to incentivize brand advocacy.
· Ensure he submits our drug to the regional hospital formulary committee before September.
· Success Metric: 25% increase in territory prescription volume.
Commercial Tier: Gold Tier ($1.2M annual territory prescription potential).
Commercial Goal: Flip Dr. Vance from prescribing standard-of-care temozolomide to our novel kinase inhibitor by Q4.
Tactical Plan:
· Visit Dr. Vance fortnightly with high-impact sales messaging on PFS superiority.
· Offer him a paid speaker contract on the commercial tour to incentivize brand advocacy.
· Ensure he submits our drug to the regional hospital formulary committee before September.
· Success Metric: 25% increase in territory prescription volume.
Rewritten Scientific Engagement Plan (SEP):
Expert Profile: Dr. Marcus Vance, MD, PhD (Professor & Chief of Neuro-Oncology)
· Scientific Tier: Tier 1 (National/International Academic Expert).
· Academic Credentials: PI on 6 Phase II/III glioblastoma trials, lead author on 24 peer-reviewed neuro-oncology publications, active member of the Society for Neuro-Oncology (SNO) guideline committee.
· Scientific Interests: Overcoming blood-brain barrier penetration limitations and mechanisms of resistance in MGMT-unmethylated glioblastoma.
Scientific Baseline & Evidence Gaps:
· Dr. Vance currently considers existing kinase inhibitor trial data limited regarding durability in recurrent disease. He has identified an evidence gap concerning sequencing after radiotherapy failure.
Annual Medical Objectives:
1. Engage Dr. Vance in scientific dialogue regarding biomarker stratification methodologies in recurrent high-grade glioma.
2. Explore his interest in participating in the Global Phase III Advisory Board evaluating second-line combination endpoints.
3. Discuss prospective investigator-initiated research concept regarding CNS pharmacokinetic cerebrospinal fluid (CSF) sampling.
Milestone Touchpoint Schedule:
· Q2 (SNO Annual Congress): 1-on-1 scientific discussion on Phase II pharmacokinetic sub-study data.
· Q3: Advisory Board participation (subject to formal expertise criteria and FMV contract).
· Q4: Scientific follow-up on investigator-initiated study (IIS) protocol concept feasibility.
Medical Value Metrics: Delivery of strategic insights on CNS sequencing challenges; successful execution of advisory board mandate. (Prescribing volume, formulary advocacy, and commercial incentives entirely eliminated).
Expert Profile: Dr. Marcus Vance, MD, PhD (Professor & Chief of Neuro-Oncology)
· Scientific Tier: Tier 1 (National/International Academic Expert).
· Academic Credentials: PI on 6 Phase II/III glioblastoma trials, lead author on 24 peer-reviewed neuro-oncology publications, active member of the Society for Neuro-Oncology (SNO) guideline committee.
· Scientific Interests: Overcoming blood-brain barrier penetration limitations and mechanisms of resistance in MGMT-unmethylated glioblastoma.
Scientific Baseline & Evidence Gaps:
· Dr. Vance currently considers existing kinase inhibitor trial data limited regarding durability in recurrent disease. He has identified an evidence gap concerning sequencing after radiotherapy failure.
Annual Medical Objectives:
1. Engage Dr. Vance in scientific dialogue regarding biomarker stratification methodologies in recurrent high-grade glioma.
2. Explore his interest in participating in the Global Phase III Advisory Board evaluating second-line combination endpoints.
3. Discuss prospective investigator-initiated research concept regarding CNS pharmacokinetic cerebrospinal fluid (CSF) sampling.
Milestone Touchpoint Schedule:
· Q2 (SNO Annual Congress): 1-on-1 scientific discussion on Phase II pharmacokinetic sub-study data.
· Q3: Advisory Board participation (subject to formal expertise criteria and FMV contract).
· Q4: Scientific follow-up on investigator-initiated study (IIS) protocol concept feasibility.
Medical Value Metrics: Delivery of strategic insights on CNS sequencing challenges; successful execution of advisory board mandate. (Prescribing volume, formulary advocacy, and commercial incentives entirely eliminated).
Reflection
Why does basing KOL tiering on prescription volume violate international anti-bribery and anti-kickback laws?
Next module
3.2 — Engagement guides and FAQs
Week 3 · Module 2
Engagement guides and FAQs
Resources that support consistent dialogue without becoming scripts — and the reactive content that must never be volunteered
Your scenario
The engagement guide contains a section headed “If the clinician raises tolerability concerns…” followed by suggested responses. Read as written, that is objection handling — a commercial technique, in a medical document, and a reviewer will name it as such.
What a guide is and is not
| A scientific engagement guide | Not this |
|---|---|
| Approved scientific topics with supporting references | A script to be delivered |
| Questions that open genuine dialogue | Questions engineered to lead to a message |
| Where to find data on each topic | Responses to anticipated objections |
| Which questions go to medical information | Ways to keep a conversation on-product |
| What insights to listen for | Prescribing intent to detect and report |
The language test
Read the guide for its verbs. Objection, overcome, address concerns, reposition, message, key takeaway, drive — all are commercial vocabulary, and their presence in a medical document is the clearest signal that the boundary has drifted.
Medical vocabulary is different: discuss, explore, provide, reference, clarify, capture, route. The words are not cosmetic; they describe different activities.
Medical vocabulary is different: discuss, explore, provide, reference, clarify, capture, route. The words are not cosmetic; they describe different activities.
Reactive-only content
| Requirement | Why |
|---|---|
| Clearly marked as reactive-only | Visually distinct, so it cannot be used by accident |
| Used only on unsolicited request | Volunteering it converts it into promotion of an unapproved use |
| Documented when used | Off-label interactions are separately tracked |
| Balanced, including negative data | Same standard as any medical information response |
| Never in a deck that gets shown | A carried deck is proactive by construction |
Drills
Drill 1 of 3
An engagement guide contains a section on "handling tolerability objections". What is the problem?
AObjection handling is a commercial activity; reframe as a scientific topic with the data
BNone — anticipating questions is sensible
COnly a problem if the section is long
DOnly a problem if the responses are unreferenced
Drill 2 of 3
How should reactive-only content be presented in an FAQ document?
AFormatted identically to the rest
BVisually distinct and explicitly marked reactive-only
CMixed through the document so it is available when needed
DNoted once in an appendix
Drill 3 of 3
Which question belongs in a scientific engagement guide?
A“Would you consider using this for your next eligible patient?”
B“What would it take for you to switch?”
C“How are you currently approaching sequencing after second-line failure?”
D“Do you agree the efficacy data are compelling?”
Production drill
Rewrite this engagement guide section so it is a medical document.
Topic: Tolerability
Key message: The safety profile is manageable and consistent with the class.
If the clinician objects that toxicity is a concern:
· Acknowledge the concern
· Reposition toward the efficacy benefit
· Highlight that only 8% discontinued
· Ask what would give them confidence to try it
Desired outcome: clinician is comfortable initiating therapy.
Key message: The safety profile is manageable and consistent with the class.
If the clinician objects that toxicity is a concern:
· Acknowledge the concern
· Reposition toward the efficacy benefit
· Highlight that only 8% discontinued
· Ask what would give them confidence to try it
Desired outcome: clinician is comfortable initiating therapy.
Rewritten
Scientific topic: safety and tolerability
What the evidence shows
· Grade ≥3 treatment-emergent adverse events: 147/389 (37.8%) versus 121/388 (31.2%) [ref]
· Most frequent grade ≥3 events: neutropenia 12.1% vs 4.6%; fatigue 8.5% vs 6.4% [ref]
· Discontinuation due to adverse events: 31/389 (8.0%) versus 22/388 (5.7%) [ref]
· No treatment-related deaths were reported [ref]
· Monitoring and dose modification are described in the label, section 4.2 [ref]
Limitations to state
· Safety data derive from a trial population with ECOG 0–2; experience in poorer performance status is limited
· No head-to-head comparative tolerability data are available
Questions that open dialogue
· How are you currently monitoring for haematological toxicity in this setting?
· What has your experience been with dose modification in similar agents?
· Which aspects of the safety profile would you want more data on?
Route to medical information
· Any question about use outside the approved indication
· Any request for data not in this guide
Insights to capture
· Monitoring practices that vary by centre
· Evidence gaps clinicians identify around tolerability
Six things removed:
1. “Key message” — medical materials provide data, not messages.
2. “Objects” and “reposition” — commercial vocabulary describing a commercial activity.
3. “Only 8%” — only editorialises; the figure is given with its denominator instead.
4. “What would give them confidence to try it” — a prescribing-intent question.
5. “Desired outcome: clinician is comfortable initiating therapy” — a commercial objective, and the clearest single indicator that this was not a medical document.
6. “Manageable and consistent with the class” — unreferenced characterisation.
What was added: limitations, routing instructions, and insights to listen for. A medical guide has all three; a commercial one has none of them.
Scientific topic: safety and tolerability
What the evidence shows
· Grade ≥3 treatment-emergent adverse events: 147/389 (37.8%) versus 121/388 (31.2%) [ref]
· Most frequent grade ≥3 events: neutropenia 12.1% vs 4.6%; fatigue 8.5% vs 6.4% [ref]
· Discontinuation due to adverse events: 31/389 (8.0%) versus 22/388 (5.7%) [ref]
· No treatment-related deaths were reported [ref]
· Monitoring and dose modification are described in the label, section 4.2 [ref]
Limitations to state
· Safety data derive from a trial population with ECOG 0–2; experience in poorer performance status is limited
· No head-to-head comparative tolerability data are available
Questions that open dialogue
· How are you currently monitoring for haematological toxicity in this setting?
· What has your experience been with dose modification in similar agents?
· Which aspects of the safety profile would you want more data on?
Route to medical information
· Any question about use outside the approved indication
· Any request for data not in this guide
Insights to capture
· Monitoring practices that vary by centre
· Evidence gaps clinicians identify around tolerability
Six things removed:
1. “Key message” — medical materials provide data, not messages.
2. “Objects” and “reposition” — commercial vocabulary describing a commercial activity.
3. “Only 8%” — only editorialises; the figure is given with its denominator instead.
4. “What would give them confidence to try it” — a prescribing-intent question.
5. “Desired outcome: clinician is comfortable initiating therapy” — a commercial objective, and the clearest single indicator that this was not a medical document.
6. “Manageable and consistent with the class” — unreferenced characterisation.
What was added: limitations, routing instructions, and insights to listen for. A medical guide has all three; a commercial one has none of them.
Reflection
Search a guide you have seen for the words objection, message, overcome and drive. What did you find?
Next module
3.3 — Advisory boards
Week 3 · Module 3
Advisory boards
A genuine need for advice, a defined question, and experts selected for expertise. Everything else is a promotional meeting in disguise
Your scenario
The advisory board agenda is 80% presentation and 20% discussion. Participants were selected from the top prescribers list. The stated objective is to “align key experts on the value proposition”. Every one of those three facts is a compliance finding, and together they describe a promotional meeting with an advisory board's name on it.
Four legitimacy tests
| # | Test | Failure looks like |
|---|---|---|
| 1 | A genuine need for advice exists, documented before the board is convened | The objective is to inform, align or build advocacy |
| 2 | A defined question the company cannot answer internally | The company already knows what it wants to hear |
| 3 | Participants selected on documented expertise criteria | Selection by prescribing volume, influence or commercial value |
| 4 | The agenda is majority discussion | Mostly presentation, with a short discussion slot at the end |
The output test
A legitimate advisory board produces advice the company did not have before, recorded and acted on.
If nothing in the output would change any decision, the board did not need to exist — and its real function was to put company data in front of influential clinicians and pay them to be there. That is the finding, and it is the commonest one in this area.
If nothing in the output would change any decision, the board did not need to exist — and its real function was to put company data in front of influential clinicians and pay them to be there. That is the finding, and it is the commonest one in this area.
Materials
| Material | Requirement |
|---|---|
| Advisory board charter | Objective, question, selection criteria, agenda, outputs, documented in advance |
| Pre-read | Context needed to advise — not a product presentation |
| Discussion guide | Open questions; time allocated to discussion, not to slides |
| Presentation slides | Minimal, framing only; same MLR requirements as any material |
| Output report | The advice received, circulated to participants and to the internal function that will act on it |
| Contracts and fair market value | Documented, proportionate to time and expertise, independent of prescribing |
Drills
Drill 1 of 3
Participants for an advisory board are selected from a top-prescribers list. What is the problem?
ANone — high prescribers have the most experience
BOnly a problem if the group is large
COnly a problem if participants are paid
DSelection must be on documented expertise criteria, not prescribing volume
Drill 2 of 3
An advisory board agenda is 80% presentation, 20% discussion. What does this indicate?
AThe board is structured to deliver information, not to receive advice
BNothing — participants need context
COnly a problem if the meeting is short
DAcceptable if a pre-read was circulated
Drill 3 of 3
After the board, what should exist?
AAn attendance list and payment records
BAn output report of the advice received, circulated and acted on
CA participant satisfaction survey
DA record of prescribing changes among participants
Executive Deliverable Key Opinion Leader (KOL) Advisory Board Synthesis Rubric
An Advisory Board Executive Summary is a high-level strategic asset delivered to executive brand teams. Structure your report using the 4-Pillar Executive Framework:
| Report Pillar | Core Content Delivered | Medical Writer Best-Practice Standard |
|---|---|---|
| 1. Executive Consensus | Unanimous clinical consensus on disease unmet needs, diagnostic delays, or current standard-of-care limitations. | Distill 6 hours of debate into 3–5 bulleted core consensus statements supported by advisor voting tallies. |
| 2. Divergent Perspectives | Points of disagreement regarding trial endpoint relevance, biomarker cutoff validity, or clinical adoption hurdles. | Avoid smoothing over dissent; capture minority specialist viewpoints (e.g. academic oncologists vs. community practitioners). |
| 3. Clinical Data Feedback | Advisors' reaction to Phase II/III efficacy, safety signals (e.g. Grade 3+ diarrhea rates), and dosing convenience. | Group verbatim feedback by theme: Perceived Strengths, Key Safety Reservations, Differentiation vs. Competitors. |
| 4. Strategic Action Items | Recommended protocol amendments, sub-study publications, educational slide deck topics, or registry creation. | Assign priority tiers (Immediate, Pre-Launch, Post-Launch) with cross-functional ownership (Clinical Dev, HEOR, MedComms). |
Production drill
Fix this advisory board proposal. Identify every failure and rewrite the objective and agenda.
Proposal
Objective: Align key experts on the value proposition ahead of launch.
Participants: 12 clinicians from the top-prescriber list in the three highest-value territories.
Agenda (4 hours): Welcome (15 min) · Product data presentation (90 min) · Competitor landscape (45 min) · Discussion (30 min) · Next steps and advocacy planning (30 min) · Lunch
Output: Summary of participant feedback on the messaging.
Payment: Honorarium scaled to participant seniority and territory value.
Objective: Align key experts on the value proposition ahead of launch.
Participants: 12 clinicians from the top-prescriber list in the three highest-value territories.
Agenda (4 hours): Welcome (15 min) · Product data presentation (90 min) · Competitor landscape (45 min) · Discussion (30 min) · Next steps and advocacy planning (30 min) · Lunch
Output: Summary of participant feedback on the messaging.
Payment: Honorarium scaled to participant seniority and territory value.
Six failures:
1. Objective is to align, not to seek advice. “Value proposition” is commercial language and there is no question being asked.
2. Selection by prescribing volume and territory value — commercial criteria, not expertise.
3. Agenda is 135 minutes of presentation to 30 minutes of discussion. The ratio states the real purpose.
4. “Advocacy planning” — building advocacy is a promotional objective and has no place on an advisory board agenda.
5. Output is feedback on messaging, which is market research, not scientific advice — and market research has its own separate rules.
6. Payment scaled to seniority and territory value — must be fair market value for time and expertise, independent of commercial value.
Rewritten
Objective: To obtain expert advice on the design of a planned real-world study in second-line disease, specifically on which outcomes are most clinically meaningful, which comparators are most relevant to current practice, and what data sources are feasible across differing health systems.
Participants: 8–10 clinicians selected against documented criteria — published research in the disease area, experience of real-world study design, and diversity of practice setting and geography. Selection documented and applied before invitations. Prescribing data not used.
Agenda (4 hours):
· Welcome, objective and declaration of interests — 15 min
· Pre-read recap and framing of the advisory question — 20 min
· Discussion 1: which outcomes matter clinically — 60 min
· Discussion 2: comparators and standard of care across settings — 60 min
· Discussion 3: feasibility and data sources — 45 min
· Summary of advice received and confirmation with participants — 20 min
Output: A report of the advice received, circulated to participants for accuracy and to the medical team responsible for the study protocol, with a record of how it changed the design.
Payment: Fair market value for time and expertise, on a documented rate, identical for all participants regardless of seniority or territory.
The ratio flip: presentation drops from 135 minutes to 20, discussion rises from 30 to 165. That single change converts the meeting from one that delivers to one that receives — and it is the change that makes every other fix credible.
1. Objective is to align, not to seek advice. “Value proposition” is commercial language and there is no question being asked.
2. Selection by prescribing volume and territory value — commercial criteria, not expertise.
3. Agenda is 135 minutes of presentation to 30 minutes of discussion. The ratio states the real purpose.
4. “Advocacy planning” — building advocacy is a promotional objective and has no place on an advisory board agenda.
5. Output is feedback on messaging, which is market research, not scientific advice — and market research has its own separate rules.
6. Payment scaled to seniority and territory value — must be fair market value for time and expertise, independent of commercial value.
Rewritten
Objective: To obtain expert advice on the design of a planned real-world study in second-line disease, specifically on which outcomes are most clinically meaningful, which comparators are most relevant to current practice, and what data sources are feasible across differing health systems.
Participants: 8–10 clinicians selected against documented criteria — published research in the disease area, experience of real-world study design, and diversity of practice setting and geography. Selection documented and applied before invitations. Prescribing data not used.
Agenda (4 hours):
· Welcome, objective and declaration of interests — 15 min
· Pre-read recap and framing of the advisory question — 20 min
· Discussion 1: which outcomes matter clinically — 60 min
· Discussion 2: comparators and standard of care across settings — 60 min
· Discussion 3: feasibility and data sources — 45 min
· Summary of advice received and confirmation with participants — 20 min
Output: A report of the advice received, circulated to participants for accuracy and to the medical team responsible for the study protocol, with a record of how it changed the design.
Payment: Fair market value for time and expertise, on a documented rate, identical for all participants regardless of seniority or territory.
The ratio flip: presentation drops from 135 minutes to 20, discussion rises from 30 to 165. That single change converts the meeting from one that delivers to one that receives — and it is the change that makes every other fix credible.
Reflection
Think of an advisory board you know of. What proportion of the agenda was discussion?
Next module
3.4 — Disease State Education & Medical Training
Week 3 · Module 4
Disease State Education & Internal Medical Training
Authoring unbranded disease awareness slide decks, pathophysiology backgrounders, and compliant internal medical training curricula
Your scenario
Your biotech company is preparing for the pre-launch phase of an investigational therapy for Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare complement-mediated hematological disorder. You are asked to author two deliverables: (1) an unbranded Disease State Education (DSE) master slide deck for external clinician education, and (2) an internal medical training manual for non-medical field personnel. The commercial lead asks you to include slides highlighting the unique advantages of the company's investigational C5 complement inhibitor. You must reject brand placement and establish rigorous non-promotional educational boundaries.
Disease State Education (DSE) — also referred to as non-branded medical education or disease awareness — is a core Medical Affairs deliverable designed to raise clinical awareness of unmet medical needs, diagnostic pathways, disease epidemiology, and underlying pathophysiology. DSE materials are deployed prior to drug approval or alongside on-market therapies to support healthcare professionals in identifying underdiagnosed conditions.
Because DSE materials are frequently utilized prior to commercial launch, they operate under strict pre-approval regulatory scrutiny (FDA "Help-Seeking" guidelines, 21 CFR 312.7, and EFPIA Code Article 3). An unbranded educational deliverable must never serve as a veiled 'pre-marketing' tool. If an educational deck focuses disproportionately on a specific biological pathway that exclusively matches the sponsor's pipeline asset while ignoring alternative validated therapeutic mechanisms, regulatory agencies will reclassify the material as unlawful pre-approval promotion.
Compliance Governance Unbranded Disease State Education (DSE) vs. Commercial Promotion
Medical writers must maintain strict boundaries between pure disease awareness and promotional product positioning:
| Deliverable Parameter | Unbranded Disease State Education (DSE) | Promotional Product Deliverables |
|---|---|---|
| Primary Objective | Educate on disease burden, natural history, diagnostic delays, and pathophysiology. | Differentiate product efficacy, promote brand adoption, and influence prescribing behavior. |
| Product & Brand Mentions | Strictly prohibited: no brand names, logos, or pipeline investigational codes (e.g., ABC-101). | Mandatory inclusion of brand name, generic name, indication, and fair balance warnings. |
| Mechanistic Breadth | Comprehensive: covers all known pathophysiological pathways and standard-of-care modalities. | Focused: highlights the specific mechanism and receptor selectivity of the commercial product. |
| Timing & Permissibility | Permissible across entire product lifecycle, including years prior to regulatory approval. | Strictly prohibited prior to regulatory approval (violates pre-approval promotion bans). |
| MLR / PRC Review Lens | Reviewed for scientific completeness, balanced disease representation, and absence of commercial bias. | Reviewed for promotional substantiation, fair balance juxtaposition, and FDA OPDP submission. |
Internal Medical Training Manuals
In addition to external education, medical writers develop Internal Medical Training Manuals to educate internal colleagues (commercial sales representatives, MSLs, clinical operations, and regulatory teams) on the therapeutic domain. Writing for internal audiences requires a specialized pedagogical approach:
- Scientific Accuracy without Over-Simplification: Deconstruct complex immunologic or oncogenic cascades into clear, modular learning chapters with glossary support and anatomical diagrams.
- Distinction between Scientific Understanding and External Promotion: Training materials must clearly instruct commercial teams that internal disease knowledge is for background comprehension only and cannot be repeated externally as unapproved off-label claims.
- Knowledge Checks & Competency Assessments: Every internal module must terminate in validated comprehension questions to ensure cross-functional teams meet mandatory compliance standards.
Drills
Drill 1 of 3
An unbranded disease awareness slide deck for Heart Failure focuses 90% of its content on the SGLT2 pathway, while ignoring ACE inhibitors, ARBs, and beta-blockers. How will regulators view this?
ACompliant — SGLT2 inhibitors represent the newest published scientific evidence
BCompliant provided the brand logo is not displayed on the slides
CDisguised product promotion: an unbranded deck must present a comprehensive, balanced overview of all established pathways
DOnly an issue if the presentation exceeds 30 minutes in length
Drill 2 of 3
Which element is strictly prohibited in an unbranded Disease State Education (DSE) backgrounder?
AEpidemiology and global prevalence statistics for the condition
BValidated diagnostic criteria published by professional medical societies
CA description of remaining unmet clinical needs in standard-of-care therapies
DThe sponsor's proprietary product trademark or pipeline investigational drug code
Drill 3 of 3
When authoring an internal medical training module for commercial sales representatives, what critical disclaimer must appear?
AA clear designation: 'For Internal Training Only — Not for External Use or Distribution to HCPs'
BAn instruction directing sales reps to leave the training booklet with target prescribers
CA calculation of the sales bonus associated with achieving therapeutic area mastery
DAn authorization for commercial reps to answer off-label questions if they score >90% on the quiz
Production drill
Audit this draft slide outline for an unbranded Disease Awareness symposium and identify all violations.
Draft Slide Outline: "Understanding Unmet Needs in Systemic Mastocytosis"
· Slide 1 (Title): Navigating Systemic Mastocytosis & The Role of KIT D816V Inhibition (Brought to you by Apex Pharma & BrandName™).
· Slide 2 (Clinical Burden): Severe anaphylaxis, debilitating bone pain, gastrointestinal distress.
· Slide 3 (Diagnostic Pathway): Bone marrow biopsy and serum tryptase thresholds.
· Slide 4 (Therapeutic Landscape): Why legacy antihistamines and cladribine fail in >80% of patients.
· Slide 5 (The Solution): Introduction of our investigational selective KIT inhibitor APX-401 — demonstrating a 72% symptom reduction in ongoing Phase II trials.
· Slide 1 (Title): Navigating Systemic Mastocytosis & The Role of KIT D816V Inhibition (Brought to you by Apex Pharma & BrandName™).
· Slide 2 (Clinical Burden): Severe anaphylaxis, debilitating bone pain, gastrointestinal distress.
· Slide 3 (Diagnostic Pathway): Bone marrow biopsy and serum tryptase thresholds.
· Slide 4 (Therapeutic Landscape): Why legacy antihistamines and cladribine fail in >80% of patients.
· Slide 5 (The Solution): Introduction of our investigational selective KIT inhibitor APX-401 — demonstrating a 72% symptom reduction in ongoing Phase II trials.
Violations & Recommended Corrections:
1. Brand Logo & Trademark on Slide 1: Including "BrandName™" on an unbranded disease education deck destroys its regulatory non-promotional status. Correction: Remove brand name. State simple corporate educational sponsorship: "Organized and funded by Apex Pharmaceuticals as an educational service for healthcare professionals."
2. Disparagement of Standard Therapies on Slide 4: Stating that legacy treatments "fail in >80%" without providing full cited context or acknowledging their guideline-endorsed palliative role creates biased commercial framing. Correction: Objectively describe current standard-of-care symptom management and note documented evidence gaps.
3. Unlawful Pre-Approval Promotion on Slide 5: Introducing pipeline asset "APX-401" and citing Phase II efficacy percentages in an unbranded symposium constitutes direct off-label / pre-approval promotion (violation of FDA 21 CFR 312.7 and EFPIA Code). Correction: Delete Slide 5 entirely. Replace with a balanced overview of "Emerging Molecular Targets and Future Research Directions in Mast Cell Biology" covering all active research pathways across the industry objectively without product-specific claims.
1. Brand Logo & Trademark on Slide 1: Including "BrandName™" on an unbranded disease education deck destroys its regulatory non-promotional status. Correction: Remove brand name. State simple corporate educational sponsorship: "Organized and funded by Apex Pharmaceuticals as an educational service for healthcare professionals."
2. Disparagement of Standard Therapies on Slide 4: Stating that legacy treatments "fail in >80%" without providing full cited context or acknowledging their guideline-endorsed palliative role creates biased commercial framing. Correction: Objectively describe current standard-of-care symptom management and note documented evidence gaps.
3. Unlawful Pre-Approval Promotion on Slide 5: Introducing pipeline asset "APX-401" and citing Phase II efficacy percentages in an unbranded symposium constitutes direct off-label / pre-approval promotion (violation of FDA 21 CFR 312.7 and EFPIA Code). Correction: Delete Slide 5 entirely. Replace with a balanced overview of "Emerging Molecular Targets and Future Research Directions in Mast Cell Biology" covering all active research pathways across the industry objectively without product-specific claims.
Reflection
How do you manage cross-functional pressure when commercial colleagues ask to insert pipeline advantages into unbranded education?
Next module
4.1 — Insight capture
Week 4 · Module 1
Insight capture
The function's most valuable output and its least taught. An insight is not what a clinician said — it is what it implies
Your scenario
A year of insight reports reads: “Dr A found the data interesting.” “Dr B was positive about the safety profile.” None of it can be acted on, and the medical strategy team stopped reading the reports six months ago.
Definition
Scientific insight
An observation from a scientific interaction that has implications for medical strategy.
It identifies an evidence gap, an unmet clinical need, a practice pattern, a misunderstanding of the data, or a barrier to appropriate use. It is specific, it is actionable, and it would change something if enough people said it.
What a clinician thought of your data is not an insight. What a clinician cannot do because the evidence does not exist is.
It identifies an evidence gap, an unmet clinical need, a practice pattern, a misunderstanding of the data, or a barrier to appropriate use. It is specific, it is actionable, and it would change something if enough people said it.
What a clinician thought of your data is not an insight. What a clinician cannot do because the evidence does not exist is.
Not an insight
An insight
Dr A found the data interestingno implication
Clinicians in this centre cannot sequence after second-line failure because no comparative data exist for the available options
Dr B was positive about safetya reaction, not an observation
Monitoring practice for haematological toxicity varies widely between centres; several are using schedules not supported by the label
Dr C asked about renal impairmenta question, not an insight
Repeated questions on dosing below CrCl 30 suggest an evidence gap in a population clinicians are treating anyway
Good meeting, will follow up
Clinicians consistently misread the subgroup analysis as establishing a predictive biomarker — suggesting our materials are unclear on the interaction test
Insights only matter in aggregate
One clinician saying sequencing is unclear is an anecdote. Forty clinicians across six countries saying it is a case for a study, a publication, or a change in medical strategy.
This is why insights must be captured in a structured system with consistent categories — free text in an email cannot be aggregated, and an insight that cannot be aggregated has no value.
This is why insights must be captured in a structured system with consistent categories — free text in an email cannot be aggregated, and an insight that cannot be aggregated has no value.
Two things insight capture is not
It is not commercial intelligence. Prescribing intentions, competitor activity, formulary status and account information belong to the commercial function and must not be gathered or reported by field medical. Doing so is one of the fastest ways to lose the independence that justifies the role.
It is not a substitute for adverse event reporting. If a clinician mentions a patient event during an insight conversation, that is a pharmacovigilance obligation, captured and forwarded separately — not recorded as an insight.
It is not a substitute for adverse event reporting. If a clinician mentions a patient event during an insight conversation, that is a pharmacovigilance obligation, captured and forwarded separately — not recorded as an insight.
Drills
Drill 1 of 3
Which is a genuine insight?
A“Dr A was impressed by the PFS data.”
B“Clinicians cannot sequence after second-line failure because no comparative data exist.”
C“Dr B intends to start using the product next quarter.”
D“The competitor’s representative visited last week.”
Drill 2 of 3
During an insight conversation, a clinician mentions a patient who developed a serious rash. What happens?
ARecord it as a safety insight
BNothing — it was an informal conversation
CCapture and forward it as an adverse event
DAsk whether they want it reported
Drill 3 of 3
Why must insights be captured in a structured system rather than free-text emails?
AIt is easier to store
BIt is a regulatory requirement
CIt lets managers measure individual output
DOnly aggregated insights have value, and free text cannot be aggregated
Production drill
Convert each raw note into a properly written insight, or say why it is not one.
1. "Dr K said the biomarker subgroup means we should be testing everyone."
2. "Dr L thought the deck was clear and well presented."
3. "Dr M asked three times about dosing in dialysis patients."
4. "Dr N mentioned a patient who had severe mucositis and stopped treatment."
5. "Dr P said the competitor's rep had been in the week before."
6. "Dr Q's centre monitors bloods weekly for the first month; the neighbouring centre does fortnightly."
2. "Dr L thought the deck was clear and well presented."
3. "Dr M asked three times about dosing in dialysis patients."
4. "Dr N mentioned a patient who had severe mucositis and stopped treatment."
5. "Dr P said the competitor's rep had been in the week before."
6. "Dr Q's centre monitors bloods weekly for the first month; the neighbouring centre does fortnightly."
1. Insight. “Clinicians are interpreting the prespecified subgroup interaction as establishing a predictive biomarker. This suggests our materials do not adequately convey that the trial was not powered for interaction, and that the finding is hypothesis-generating.” — Note what the insight is: not that Dr K wants testing, but that our communication is being misread. That is actionable.
2. Not an insight. Feedback on materials. Useful to pass to whoever owns the deck, but it has no strategic implication and should not enter the insight system.
3. Insight. “Repeated questions about dosing in dialysis suggest clinicians are treating this population despite the absence of dosing guidance. This is an evidence gap with a potential safety dimension.” — Three questions from one clinician is weak; the same insight from twenty is a case for a PK study.
4. Not an insight — this is an adverse event. Capture and forward through pharmacovigilance immediately. Do not route it into the insight system instead, and do not delay it because the conversation was about something else.
5. Not an insight, and must not be recorded. Competitor field activity is commercial intelligence. Gathering or reporting it is outside the medical remit and compromises the function's independence.
6. Insight. “Monitoring schedules for haematological toxicity vary substantially between centres in this region, with some using intervals not specified in the label. This suggests a need to clarify the label-recommended schedule in our materials.” — Practice variation is one of the most valuable insight categories and the most often overlooked, because nobody asked a question.
Three of six are insights, one is an adverse event, one is feedback, and one must not be recorded at all. That distribution is realistic. The discipline is knowing which pile each note goes in before you write anything down.
2. Not an insight. Feedback on materials. Useful to pass to whoever owns the deck, but it has no strategic implication and should not enter the insight system.
3. Insight. “Repeated questions about dosing in dialysis suggest clinicians are treating this population despite the absence of dosing guidance. This is an evidence gap with a potential safety dimension.” — Three questions from one clinician is weak; the same insight from twenty is a case for a PK study.
4. Not an insight — this is an adverse event. Capture and forward through pharmacovigilance immediately. Do not route it into the insight system instead, and do not delay it because the conversation was about something else.
5. Not an insight, and must not be recorded. Competitor field activity is commercial intelligence. Gathering or reporting it is outside the medical remit and compromises the function's independence.
6. Insight. “Monitoring schedules for haematological toxicity vary substantially between centres in this region, with some using intervals not specified in the label. This suggests a need to clarify the label-recommended schedule in our materials.” — Practice variation is one of the most valuable insight categories and the most often overlooked, because nobody asked a question.
Three of six are insights, one is an adverse event, one is feedback, and one must not be recorded at all. That distribution is realistic. The discipline is knowing which pile each note goes in before you write anything down.
Reflection
Write one insight from a recent professional conversation, in the form used above. Is it specific enough to act on?
Next module
4.2 — Investigator-Initiated Studies & Research Grants
Week 4 · Module 2
Investigator-Initiated Studies (IIS/IST) & Research Grants
Managing unsolicited investigator research proposals, Medical Review Committee (MRC) charters, and drug supply agreements
Your scenario
A prominent academic thoracic oncologist submits an unsolicited Investigator-Initiated Study (IIS) concept requesting $300,000 in grant funding and 120 vials of your company's approved checkpoint inhibitor to conduct a Phase II study in rare thymic carcinomas. The commercial team wants to approve the grant immediately because the institution is a high-volume purchasing center. As the Medical Affairs scientific lead, you must protect company compliance by routing the proposal through the independent Medical Review Committee (MRC), ensuring the budget reflects Fair Market Value (FMV), and verifying that the investigator assumes full legal and regulatory sponsor responsibilities under FDA 21 CFR 312.3.
Investigator-Initiated Studies (IIS) — also referred to as Investigator-Sponsored Trials (ISTs) or Investigator-Sponsored Research (ISR) — are clinical or preclinical research studies conceptualized, designed, and executed by independent academic investigators or medical institutions. In an IIS, the academic clinician serves as the regulatory Sponsor-Investigator, assuming full legal responsibility for trial conduct, Ethics Committee / IRB approvals, safety reporting, and publication.
Because pharmaceutical companies may provide financial support (grants) or investigational drug supplies (in-kind support) to external investigators, IIS programs are subject to strict anti-kickback, anti-bribery, and off-label promotion regulations. Grants must never be used to reward past prescribing or incentivize future product adoption. The entire program must be administered exclusively by Medical Affairs through an independent Medical Review Committee (MRC) with zero commercial input.
Regulatory Governance Company-Sponsored Clinical Trials vs. Investigator-Initiated Studies (IIS/IST)
Medical writers and Medical Affairs scientists must understand the precise legal division of responsibilities in collaborative research:
| Regulatory Dimension | Company-Sponsored Trial (Pivotal Phase I–III) | Investigator-Initiated Study (IIS / IST) |
|---|---|---|
| Legal Sponsor Identity | The Pharmaceutical Sponsor (holds IND/CTA, audits sites, contracts CROs). | The Academic Investigator or Medical Institution (holds IND/CTA as Sponsor-Investigator). |
| Protocol Authoring & Design | Penned and finalized by Company Clinical Development & Regulatory teams. | Independently authored by the Investigator; company review is strictly for scientific safety/feasibility. |
| Pharmacovigilance (SAE/SUSAR) | Company manages safety database and reports directly to global health authorities. | Sponsor-Investigator reports directly to IRB/Ethics Committees and FDA/EMA; company receives safety data for aggregate filing. |
| Data Ownership & Publications | Company owns raw database, clinical study report (CSR), and directs publication timeline. | Investigator owns raw clinical database and retains 100% independent academic publication rights. |
| Commercial Involvement | Commercial team provides market forecasting and target product profile inputs. | Strictly Prohibited: Commercial teams have zero voting rights, screening roles, or funding influence in MRC. |
The Medical Review Committee (MRC) Evaluation Rubric
When an unsolicited IIS proposal is received, the Medical Affairs review team evaluates the concept sheet against 4 core evaluation pillars:
- Scientific Merit & Innovation: Does the protocol address a genuine clinical unmet need, test a robust biological hypothesis, or provide valuable real-world efficacy/safety data?
- Patient Safety & Risk-Benefit: Is the dosing rationale sound? Are safety monitoring schedules, dose-modification criteria, and toxicity management protocols aligned with the established safety profile?
- Investigator & Site Feasibility: Does the investigator have documented track records in clinical trial execution, adequate patient catchment volumes, and dedicated study coordinator infrastructure?
- Budget & Fair Market Value (FMV): Is every line item (nursing costs, biomarker assays, imaging scans) costed at documented, objective Fair Market Value without excessive overhead or disguised compensation?
Drills
Drill 1 of 3
A commercial sales representative hears that an oncologist wants to study an off-label combination and offers to write the IIS protocol for them. What is the compliance violation?
ASevere violation: company personnel cannot solicit, conceive, or ghostwrite investigator-sponsored protocols
BNo violation — assisting investigators with medical writing accelerates scientific research
CAcceptable provided the sales representative has a scientific undergraduate degree
DOnly a violation if the total grant budget exceeds $500,000
Drill 2 of 3
Who holds legal and regulatory responsibility for submitting safety reports (SUSARs) to health authorities in an Investigator-Initiated Study?
AThe pharmaceutical manufacturer providing the grant funding
BThe academic investigator (acting as the regulatory Sponsor-Investigator)
CThe local hospital Institutional Review Board (IRB)
DThe central laboratory processing biomarker blood samples
Drill 3 of 3
What requirement must be satisfied regarding publication rights in a compliant Investigator-Initiated Study Agreement?
AThe company must possess the right to veto publication if the trial results are negative
BThe company must be listed as the lead primary author on all peer-reviewed manuscripts
CThe investigator retains independent publication rights regardless of trial outcome, with company review limited to confidential IP checks
DPublications are only required if the primary statistical endpoint achieves p < 0.05
Production drill
Audit this Investigator-Initiated Study (IIS) grant submission and identify all compliance red flags.
IIS Grant Application: Evaluation of Drug Z in Refractory Pancreatic Cancer
· Principal Investigator: Dr. Robert Jenkins (Member of National Formulary Committee).
· Origin of Proposal: Commercial Sales Director met with Dr. Jenkins and suggested he apply for a $400,000 grant to study Drug Z, promising the funds would be approved within 2 weeks if hospital formulary inclusion is secured.
· Protocol Design: Drafted by the company's oncology brand manager, proposing an open-label single-arm study in 20 patients.
· Budget Breakdown: $150,000 direct patient costs; $100,000 institutional overhead; $150,000 unrestricted investigator consulting fee / departmental discretionary fund.
· Publication Clause: The pharmaceutical company reserves the right to suppress publication if overall survival results fail to match Phase III benchmarks.
· Principal Investigator: Dr. Robert Jenkins (Member of National Formulary Committee).
· Origin of Proposal: Commercial Sales Director met with Dr. Jenkins and suggested he apply for a $400,000 grant to study Drug Z, promising the funds would be approved within 2 weeks if hospital formulary inclusion is secured.
· Protocol Design: Drafted by the company's oncology brand manager, proposing an open-label single-arm study in 20 patients.
· Budget Breakdown: $150,000 direct patient costs; $100,000 institutional overhead; $150,000 unrestricted investigator consulting fee / departmental discretionary fund.
· Publication Clause: The pharmaceutical company reserves the right to suppress publication if overall survival results fail to match Phase III benchmarks.
Severe Compliance & Legal Red Flags:
1. Illegal Quid Pro Quo & Anti-Kickback Violation: The commercial sales director conditioning grant approval on hospital formulary inclusion constitutes a direct violation of the US Anti-Kickback Statute (AKS) and international anti-bribery legislation. Correction: Immediate compliance escalation; commercial teams must be barred from all IIS discussions.
2. Solicitation & Company Ghostwriting: The brand manager conceiving and drafting the protocol violates the core definition of an Investigator-Initiated study. Drafting protocols for off-label indications constitutes illegal off-label promotion. Correction: Protocols must be independently conceptualized and authored by the academic investigator.
3. Disguised Compensation / Inflated Budget: A $150,000 'unrestricted discretionary fee' not tied to documented clinical trial services violates Fair Market Value (FMV) rules and represents an illegal financial kickback. Correction: Budget must be audited against objective FMV benchmark rates for clinical procedures, nursing hours, and diagnostic assays.
4. Publication Suppression Clause: Company right to block negative study results violates ICMJE guidelines, European Good Publication Practice (GPP 2022), and statutory trial transparency laws (FDAAA 801). Correction: The investigator must retain 100% independent publication rights regardless of trial outcome.
1. Illegal Quid Pro Quo & Anti-Kickback Violation: The commercial sales director conditioning grant approval on hospital formulary inclusion constitutes a direct violation of the US Anti-Kickback Statute (AKS) and international anti-bribery legislation. Correction: Immediate compliance escalation; commercial teams must be barred from all IIS discussions.
2. Solicitation & Company Ghostwriting: The brand manager conceiving and drafting the protocol violates the core definition of an Investigator-Initiated study. Drafting protocols for off-label indications constitutes illegal off-label promotion. Correction: Protocols must be independently conceptualized and authored by the academic investigator.
3. Disguised Compensation / Inflated Budget: A $150,000 'unrestricted discretionary fee' not tied to documented clinical trial services violates Fair Market Value (FMV) rules and represents an illegal financial kickback. Correction: Budget must be audited against objective FMV benchmark rates for clinical procedures, nursing hours, and diagnostic assays.
4. Publication Suppression Clause: Company right to block negative study results violates ICMJE guidelines, European Good Publication Practice (GPP 2022), and statutory trial transparency laws (FDAAA 801). Correction: The investigator must retain 100% independent publication rights regardless of trial outcome.
Reflection
Why must the Medical Review Committee (MRC) operate entirely independently of commercial sales and marketing?
Next module
4.3 — The deck clinic
Week 4 · Module 3
The deck clinic
A field deck with sixteen planted problems across architecture, referencing, balance and permissibility
How to do this
Timer at 40 minutes. Produce a findings list with corrections, marking each as rewrite, trim or delete. Do not read the rubric first.
The deck as drafted
Find every problem.
Slide 1: Product logo and the line "Redefining outcomes in advanced disease". No version, no date.
Slide 2: "Why patients need this treatment" — disease burden statistics, no references.
Slide 3: Contents (no hyperlinks). Deck is 58 slides, linear.
Slide 4: "Impressive efficacy" — median PFS 8.9 vs 5.2 months, HR 0.66. Ref: pivotal publication.
Slide 5: Forest plot, 11 subgroups, no interaction p values. Title: "Consistent benefit across all patient groups."
Slide 6: "Favourable tolerability" — your grade ≥3 rate (37.8%) beside competitor's published rate (41%). Both referenced.
Slide 7: Real-world cohort response rate 39%. Ref: congress abstract, 2022. No design limitations stated.
Slide 8: "Emerging evidence in first line" — published Phase II. Product approved second line only.
Slide 9: "Pooled safety analysis" — Ref: "Internal analysis, Table 14.3.7."
Slide 10: "What's next" — the pipeline compound, Phase III ongoing, expected submission next year.
Slide 11: Renal dosing. Ref: pivotal publication.
Slide 12: References. Includes two sources not cited on any slide.
Slide 2: "Why patients need this treatment" — disease burden statistics, no references.
Slide 3: Contents (no hyperlinks). Deck is 58 slides, linear.
Slide 4: "Impressive efficacy" — median PFS 8.9 vs 5.2 months, HR 0.66. Ref: pivotal publication.
Slide 5: Forest plot, 11 subgroups, no interaction p values. Title: "Consistent benefit across all patient groups."
Slide 6: "Favourable tolerability" — your grade ≥3 rate (37.8%) beside competitor's published rate (41%). Both referenced.
Slide 7: Real-world cohort response rate 39%. Ref: congress abstract, 2022. No design limitations stated.
Slide 8: "Emerging evidence in first line" — published Phase II. Product approved second line only.
Slide 9: "Pooled safety analysis" — Ref: "Internal analysis, Table 14.3.7."
Slide 10: "What's next" — the pipeline compound, Phase III ongoing, expected submission next year.
Slide 11: Renal dosing. Ref: pivotal publication.
Slide 12: References. Includes two sources not cited on any slide.
The sixteen problems
Architecture (4)
1. Slide 1 has no front matter — no intended use, audience, non-promotional designation, indication, version, date or approval code. Rewrite.
2. “Redefining outcomes” is a promotional tagline on a scientific deck. Delete.
3. Contents not hyperlinked, deck linear across 58 slides. Rewrite as modular sections with navigation.
4. Slide 2 title “Why patients need this treatment” frames disease context as product need, and the statistics are unreferenced. Rewrite as neutral disease context with citations.
Language and balance (4)
5. “Impressive efficacy” (slide 4) — unreferenced judgement. Rewrite to state the finding.
6. “Consistent benefit across all patient groups” (slide 5) — overstates, and “all” is not supportable. Rewrite.
7. Slide 5 shows 11 subgroups with no interaction p values. Trim to the prespecified subgroups and add the interaction tests.
8. “Favourable tolerability” (slide 6) — judgement. Rewrite.
Referencing (4)
9. Slide 7 cites a 2022 congress abstract — check for a full publication and switch; identify as an abstract if it is still the only source.
10. Slide 7 has no observational design limitations. Rewrite — a real-world slide shown alone must carry its own caveats.
11. Slide 9 cites an internal table number. Rewrite as data on file with a proper identifier — and first check whether a published pooled analysis exists.
12. Slide 11 cites the trial publication for a dosing recommendation. Wrong source. Rewrite to cite the label, section and version.
Permissibility — the ones that must go (4)
13. Slide 6 competitor juxtaposition — cross-trial comparison, invalid. Delete the competitor element.
14. Slide 8, first-line Phase II — off-label content in proactive material. Delete. The title alone promotes an unapproved use.
15. Slide 10, pipeline compound with expected submission timing — pre-approval communication. Delete.
16. Slide 12 has two orphan references. Remove them, or find the slides that lost their citations.
Scoring
13–16 — pass. You would catch this before MLR did.
8–12 — close. Note whether your misses were craft (1–12) or permissibility (13–16).
Under 8 — redo Modules 1.2 to 2.3.
The category that matters: problems 1–12 produce a deck that comes back from MLR with 40 comments. Problems 13–16 produce a deck that, if it somehow cleared review and went into the field, would be a compliance incident. Three slides cannot be fixed and must be deleted — and each of them is accurate, referenced and scientifically sound, which is precisely why they get drafted.
Architecture (4)
1. Slide 1 has no front matter — no intended use, audience, non-promotional designation, indication, version, date or approval code. Rewrite.
2. “Redefining outcomes” is a promotional tagline on a scientific deck. Delete.
3. Contents not hyperlinked, deck linear across 58 slides. Rewrite as modular sections with navigation.
4. Slide 2 title “Why patients need this treatment” frames disease context as product need, and the statistics are unreferenced. Rewrite as neutral disease context with citations.
Language and balance (4)
5. “Impressive efficacy” (slide 4) — unreferenced judgement. Rewrite to state the finding.
6. “Consistent benefit across all patient groups” (slide 5) — overstates, and “all” is not supportable. Rewrite.
7. Slide 5 shows 11 subgroups with no interaction p values. Trim to the prespecified subgroups and add the interaction tests.
8. “Favourable tolerability” (slide 6) — judgement. Rewrite.
Referencing (4)
9. Slide 7 cites a 2022 congress abstract — check for a full publication and switch; identify as an abstract if it is still the only source.
10. Slide 7 has no observational design limitations. Rewrite — a real-world slide shown alone must carry its own caveats.
11. Slide 9 cites an internal table number. Rewrite as data on file with a proper identifier — and first check whether a published pooled analysis exists.
12. Slide 11 cites the trial publication for a dosing recommendation. Wrong source. Rewrite to cite the label, section and version.
Permissibility — the ones that must go (4)
13. Slide 6 competitor juxtaposition — cross-trial comparison, invalid. Delete the competitor element.
14. Slide 8, first-line Phase II — off-label content in proactive material. Delete. The title alone promotes an unapproved use.
15. Slide 10, pipeline compound with expected submission timing — pre-approval communication. Delete.
16. Slide 12 has two orphan references. Remove them, or find the slides that lost their citations.
Scoring
13–16 — pass. You would catch this before MLR did.
8–12 — close. Note whether your misses were craft (1–12) or permissibility (13–16).
Under 8 — redo Modules 1.2 to 2.3.
The category that matters: problems 1–12 produce a deck that comes back from MLR with 40 comments. Problems 13–16 produce a deck that, if it somehow cleared review and went into the field, would be a compliance incident. Three slides cannot be fixed and must be deleted — and each of them is accurate, referenced and scientifically sound, which is precisely why they get drafted.
Reflection
Did you catch all four delete-only items? Those are the ones where accuracy is not the test.
Next module
4.4 — Capstone and exit assessment
Week 4 · Module 4
Capstone and exit assessment
A full field medical scenario with sixteen problems across materials, activities and the boundary
How to do this
Timer at 45 minutes. Produce a findings list with corrections. Pass mark 12 of 16. Do not read the rubric first.
The scenario
Review the whole picture and find every problem.
The plan for the coming quarter, as written by a field medical lead:
"Our priority accounts this quarter are the twelve highest-volume centres, identified with the commercial team. I've asked the team to focus visits there.
The new deck is ready. It opens with our efficacy headline and includes the first-line Phase II data — it's published, so we're covered — plus a slide comparing our grade ≥3 rate with the competitor's. The pooled safety slide cites our internal analysis table.
I've added an objection-handling section to the engagement guide covering tolerability and cost.
The advisory board is confirmed: 12 top prescribers, agenda is mostly data presentation with discussion at the end, objective is to build advocacy ahead of the second-line launch. Honoraria are scaled by territory.
On insights, I've asked the team to report which clinicians are switching and what the competitor reps are saying, so we can feed that back to commercial.
One of the team mentioned a clinician told them about a patient with severe hepatic toxicity — I said to note it in the insight system."
"Our priority accounts this quarter are the twelve highest-volume centres, identified with the commercial team. I've asked the team to focus visits there.
The new deck is ready. It opens with our efficacy headline and includes the first-line Phase II data — it's published, so we're covered — plus a slide comparing our grade ≥3 rate with the competitor's. The pooled safety slide cites our internal analysis table.
I've added an objection-handling section to the engagement guide covering tolerability and cost.
The advisory board is confirmed: 12 top prescribers, agenda is mostly data presentation with discussion at the end, objective is to build advocacy ahead of the second-line launch. Honoraria are scaled by territory.
On insights, I've asked the team to report which clinicians are switching and what the competitor reps are saying, so we can feed that back to commercial.
One of the team mentioned a clinician told them about a patient with severe hepatic toxicity — I said to note it in the insight system."
The sixteen problems
Independence (3)
1. Priority accounts selected by prescribing volume, with the commercial team. Field medical activity must be directed by medical strategy and scientific need. Fix: select on scientific criteria — research activity, evidence gaps, expertise — determined by medical.
2. Visits directed at high-volume centres compounds this: the deployment pattern would look commercial to an inspector regardless of what happens in the meetings.
3. Insight reporting fed back to commercial. Scientific insights go to medical strategy. Routing field medical intelligence to commercial destroys the separation.
The deck (5)
4. Opens with the efficacy headline. Front matter first: intended use, audience, non-promotional designation, indication, version.
5. First-line Phase II included because it is published. Published is not approved. Off-label content cannot appear in proactive material. Delete; handle reactively via medical information.
6. Competitor comparison slide. Cross-trial comparison, invalid, and a comparative claim by juxtaposition. Delete.
7. Pooled safety cites an internal table number. Unusable externally. Check for a published source first; if none, use data on file with a proper identifier.
8. “It's published, so we're covered” is the underlying misconception and should be corrected explicitly with the team.
Engagement guide (2)
9. Objection-handling section — a commercial technique in a medical document. Rewrite as scientific topics with data and limitations.
10. Cost is in the guide. Pricing and cost discussions are outside the field medical remit entirely. Delete.
Advisory board (4)
11. Participants are top prescribers. Select on documented expertise criteria.
12. Agenda is mostly presentation. Flip the ratio — majority discussion.
13. Objective is to build advocacy. An advisory board must seek advice on a defined question. Rewrite the objective entirely.
14. Honoraria scaled by territory. Must be fair market value for time and expertise, identical regardless of commercial value.
Pharmacovigilance (2)
15. A reported case of severe hepatic toxicity was directed into the insight system. This is an adverse event and must be captured and forwarded to pharmacovigilance on the required timeline. The most serious item here.
16. The instruction to note it as an insight suggests the team has not been trained on AE capture — which means there are probably other missed cases. Escalate and retrain.
Scoring
12–16 — pass. You would recognise a field medical function drifting across the boundary.
8–11 — close. Note which block you missed.
Under 8 — work through Weeks 1 and 3 again.
The one to catch first: problem 15. Everything else is a compliance drift that a good MLR process or an audit would eventually catch. A missed adverse event is a patient safety and pharmacovigilance failure, and the instruction that caused it came from the person leading the team.
Independence (3)
1. Priority accounts selected by prescribing volume, with the commercial team. Field medical activity must be directed by medical strategy and scientific need. Fix: select on scientific criteria — research activity, evidence gaps, expertise — determined by medical.
2. Visits directed at high-volume centres compounds this: the deployment pattern would look commercial to an inspector regardless of what happens in the meetings.
3. Insight reporting fed back to commercial. Scientific insights go to medical strategy. Routing field medical intelligence to commercial destroys the separation.
The deck (5)
4. Opens with the efficacy headline. Front matter first: intended use, audience, non-promotional designation, indication, version.
5. First-line Phase II included because it is published. Published is not approved. Off-label content cannot appear in proactive material. Delete; handle reactively via medical information.
6. Competitor comparison slide. Cross-trial comparison, invalid, and a comparative claim by juxtaposition. Delete.
7. Pooled safety cites an internal table number. Unusable externally. Check for a published source first; if none, use data on file with a proper identifier.
8. “It's published, so we're covered” is the underlying misconception and should be corrected explicitly with the team.
Engagement guide (2)
9. Objection-handling section — a commercial technique in a medical document. Rewrite as scientific topics with data and limitations.
10. Cost is in the guide. Pricing and cost discussions are outside the field medical remit entirely. Delete.
Advisory board (4)
11. Participants are top prescribers. Select on documented expertise criteria.
12. Agenda is mostly presentation. Flip the ratio — majority discussion.
13. Objective is to build advocacy. An advisory board must seek advice on a defined question. Rewrite the objective entirely.
14. Honoraria scaled by territory. Must be fair market value for time and expertise, identical regardless of commercial value.
Pharmacovigilance (2)
15. A reported case of severe hepatic toxicity was directed into the insight system. This is an adverse event and must be captured and forwarded to pharmacovigilance on the required timeline. The most serious item here.
16. The instruction to note it as an insight suggests the team has not been trained on AE capture — which means there are probably other missed cases. Escalate and retrain.
Scoring
12–16 — pass. You would recognise a field medical function drifting across the boundary.
8–11 — close. Note which block you missed.
Under 8 — work through Weeks 1 and 3 again.
The one to catch first: problem 15. Everything else is a compliance drift that a good MLR process or an audit would eventually catch. A missed adverse event is a patient safety and pharmacovigilance failure, and the instruction that caused it came from the person leading the team.
Retake the diagnostic
Return to Module 1.1 and take the 24-item diagnostic again. The difference from your baseline is the only honest measure of what changed.
What to do next
Four habits. Before any material goes into review, search it for favourable adjectives and unreferenced claims. Ask of every slide whether it is approved for this use, not just approved. Check every engagement document for commercial vocabulary. And treat any mention of a patient event as a pharmacovigilance obligation, whatever the conversation was about.
Then pair it with the rest. Medical Information covers the reactive side of the same boundary; Congress Materials covers the public-facing side; Reading Source Documents covers where the referenced numbers come from.
Then pair it with the rest. Medical Information covers the reactive side of the same boundary; Congress Materials covers the public-facing side; Reading Source Documents covers where the referenced numbers come from.
Final reflection
Your diagnostic score at the start, and now. Which module changed how you would build field material most?
You have completed the course
Field Medical Materials
IMRAD Academy — Read like a scientist. Write like a professional.
Field Medical Materials · v2.0 (16 Modules)